aripiprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychotropics, phenylpiperazine derivatives 242 129722-12-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aripiprazole hydrate
  • aripiprazole
  • abilify
  • arpizol
  • pripiprazole
  • OPC-14597
A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.
  • Molecular weight: 448.39
  • Formula: C23H27Cl2N3O2
  • CLOGP: 5.11
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 44.81
  • ALOGS: -4.76
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
13.30 mg P
15 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.56 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.83 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 75 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2006 PMDA Otsuka Pharmaceutical Co., Ltd
June 4, 2004 EMA
Nov. 15, 2002 FDA OTSUKA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 1643.70 11.81 588 93565 8558 63386311
Tardive dyskinesia 1639.63 11.81 576 93577 7926 63386943
Dystonia 1364.34 11.81 575 93578 13244 63381625
Suicide attempt 1130.86 11.81 842 93311 60076 63334793
Extrapyramidal disorder 1102.42 11.81 489 93664 12795 63382074
Dyskinesia 996.84 11.81 610 93543 31392 63363477
Sedation 982.77 11.81 649 93504 38160 63356709
Sexual dysfunction 955.20 11.81 325 93828 4034 63390835
Blood prolactin abnormal 927.17 11.81 292 93861 2787 63392082
Suicidal ideation 818.85 11.81 704 93449 61717 63333152
Psychotic disorder 749.63 11.81 470 93683 25242 63369627
Anosognosia 734.55 11.81 247 93906 2949 63391920
Hallucination, auditory 730.10 11.81 364 93789 12460 63382409
Weight increased 725.55 11.81 1347 92806 259445 63135424
Product use in unapproved indication 721.18 11.81 1092 93061 177988 63216881
Parkinsonism 704.84 11.81 333 93820 10106 63384763
Disturbance in social behaviour 680.74 11.81 247 93906 3746 63391123
Neuroleptic malignant syndrome 665.14 11.81 335 93818 11721 63383148
Delusion 636.94 11.81 325 93828 11692 63383177
Mania 622.38 11.81 323 93830 12044 63382825
Metabolic disorder 603.22 11.81 259 93894 6244 63388625
Drug interaction 602.73 11.81 1156 92997 227975 63166894
Treatment noncompliance 574.53 11.81 462 93691 36863 63358006
Personality change 534.77 11.81 243 93910 6730 63388139
Tremor 524.22 11.81 801 93352 131438 63263431
Hyperprolactinaemia 468.99 11.81 187 93966 3713 63391156
Schizoaffective disorder 425.57 11.81 170 93983 3392 63391477
Intentional overdose 420.76 11.81 534 93619 73618 63321251
Intentional self-injury 414.56 11.81 327 93826 25360 63369509
Abnormal behaviour 412.45 11.81 303 93850 21123 63373746
Oculogyric crisis 395.44 11.81 133 94020 1588 63393281
Electrocardiogram QT prolonged 389.99 11.81 461 93692 59069 63335800
Restlessness 381.45 11.81 330 93823 29123 63365746
Agitation 328.94 11.81 424 93729 59333 63335536
Stubbornness 318.95 11.81 80 94073 291 63394578
Anxiety 296.60 11.81 849 93304 216692 63178177
Joint swelling 289.10 11.81 66 94087 327600 63067269
Salivary hypersecretion 287.89 11.81 165 93988 7501 63387368
Schizophrenia 287.61 11.81 181 93972 9771 63385098
Somnolence 271.84 11.81 726 93427 177959 63216910
Arthralgia 269.78 11.81 269 93884 569441 62825428
Gambling disorder 268.98 11.81 92 94061 1160 63393709
Aggression 267.90 11.81 245 93908 23253 63371616
Psychotic symptom 263.96 11.81 96 94057 1465 63393404
Pain 262.80 11.81 435 93718 740193 62654676
Blood glucose increased 260.53 11.81 455 93698 83301 63311568
Contraindicated product administered 256.22 11.81 17 94136 217631 63177238
Galactorrhoea 254.47 11.81 124 94029 4031 63390838
Systemic lupus erythematosus 249.87 11.81 15 94138 208903 63185966
Infusion related reaction 247.71 11.81 35 94118 245486 63149383
Psychiatric decompensation 243.77 11.81 88 94065 1313 63393556
Drug abuse 240.04 11.81 405 93748 72113 63322756
Swelling 237.83 11.81 58 94095 275320 63119549
Drug level increased 235.98 11.81 225 93928 22511 63372358
Thinking abnormal 233.47 11.81 163 93990 10480 63384389
Muscle rigidity 231.20 11.81 167 93986 11333 63383536
Arthropathy 228.76 11.81 37 94116 234755 63160114
Metabolic syndrome 222.21 11.81 85 94068 1503 63393366
Orthostatic hypertension 219.84 11.81 64 94089 454 63394415
Abdominal discomfort 219.06 11.81 101 94052 320784 63074085
Glossodynia 216.46 11.81 12 94141 178864 63216005
Blood prolactin increased 215.91 11.81 105 94048 3398 63391471
Diarrhoea 210.93 11.81 469 93684 714897 62679972
Rheumatoid arthritis 206.76 11.81 60 94093 253759 63141110
Drug intolerance 206.31 11.81 100 94053 308561 63086308
Overdose 202.27 11.81 494 93659 114584 63280285
Maternal exposure during pregnancy 201.39 11.81 750 93403 219312 63175557
Irritability 200.14 11.81 241 93912 31453 63363416
Dyspnoea 199.47 11.81 428 93725 660885 62733984
Gestational diabetes 199.30 11.81 135 94018 8261 63386608
Underdose 198.82 11.81 224 93929 27232 63367637
Depression 189.30 11.81 681 93472 195811 63199058
Rash 188.89 11.81 340 93813 560531 62834338
Prescribed underdose 187.87 11.81 226 93927 29463 63365406
Abortion spontaneous 185.42 11.81 285 93868 46910 63347959
Mental disorder 180.11 11.81 207 93946 25712 63369157
Psychiatric symptom 173.91 11.81 104 94049 5119 63389750
Psychomotor hyperactivity 170.39 11.81 135 94018 10528 63384341
Persecutory delusion 170.07 11.81 83 94070 2707 63392162
Alopecia 169.25 11.81 151 94002 337385 63057484
Diabetes mellitus 164.22 11.81 296 93857 55514 63339355
Foetal exposure during pregnancy 163.73 11.81 219 93934 31743 63363126
Suppressed lactation 159.48 11.81 49 94104 427 63394442
Hypersensitivity 155.20 11.81 124 94029 292561 63102308
Pneumonia 146.46 11.81 285 93868 456482 62938387
Mood altered 145.62 11.81 142 94011 14601 63380268
Sinusitis 141.64 11.81 80 94073 226573 63168296
Wrong technique in product usage process 141.13 11.81 296 93857 62044 63332825
Infarction 135.77 11.81 70 94083 2571 63392298
Drug monitoring procedure incorrectly performed 135.66 11.81 36 94117 172 63394697
Impulse-control disorder 135.13 11.81 49 94104 741 63394128
Mental impairment 131.79 11.81 132 94021 14019 63380850
Pregnancy 131.60 11.81 213 93940 36623 63358246
Hypersexuality 130.53 11.81 43 94110 479 63394390
Cogwheel rigidity 130.35 11.81 62 94091 1908 63392961
Discomfort 128.31 11.81 44 94109 167330 63227539
Insurance issue 127.88 11.81 91 94062 6030 63388839
Social avoidant behaviour 127.64 11.81 70 94083 2918 63391951
Fatigue 127.31 11.81 785 93368 887243 62507626
Catatonia 125.79 11.81 80 94073 4397 63390472
Blood creatine phosphokinase increased 125.50 11.81 188 93965 30242 63364627
Nasopharyngitis 124.68 11.81 116 94037 254141 63140728
Antipsychotic drug level increased 123.82 11.81 72 94081 3363 63391506
Helicobacter infection 123.22 11.81 3 94150 92782 63302087
Caesarean section 121.66 11.81 138 94015 16894 63377975
Bipolar disorder 121.26 11.81 98 94055 7862 63387007
Pericarditis 120.99 11.81 24 94129 131555 63263314
Posture abnormal 120.43 11.81 62 94091 2270 63392599
Hallucinations, mixed 120.26 11.81 80 94073 4749 63390120
Compulsive shopping 118.43 11.81 44 94109 715 63394154
Therapeutic product effect decreased 116.69 11.81 71 94082 193116 63201753
Drug hypersensitivity 112.93 11.81 179 93974 310508 63084361
Impaired healing 112.28 11.81 11 94142 102531 63292338
Hypomania 111.70 11.81 85 94068 6245 63388624
Anaemia 111.51 11.81 164 93989 293266 63101603
Logorrhoea 110.54 11.81 60 94093 2450 63392419
Lower respiratory tract infection 110.02 11.81 30 94123 132277 63262592
Hallucination 107.83 11.81 246 93907 54571 63340298
Hostility 106.10 11.81 53 94100 1819 63393050
Serotonin syndrome 105.39 11.81 168 93985 28514 63366355
Pruritus 105.27 11.81 238 93915 361215 63033654
Paranoia 105.21 11.81 107 94046 11572 63383297
Sopor 104.64 11.81 146 94007 22018 63372851
Cough 104.18 11.81 171 93982 292572 63102297
Amenorrhoea 102.64 11.81 98 94055 9816 63385053
Febrile neutropenia 102.04 11.81 25 94128 118424 63276445
Stomatitis 102.02 11.81 39 94114 138686 63256183
Blister 101.45 11.81 33 94120 129781 63265088
Hepatic enzyme increased 100.71 11.81 91 94062 202237 63192632
Impulsive behaviour 99.21 11.81 48 94105 1535 63393334
Drooling 98.55 11.81 65 94088 3803 63391066
Personality disorder 98.09 11.81 76 94077 5735 63389134
Peripheral swelling 97.78 11.81 152 94001 265790 63129079
Economic problem 97.39 11.81 51 94102 1935 63392934
Completed suicide 94.35 11.81 447 93706 145226 63249643
Infection 94.15 11.81 121 94032 229052 63165817
Treatment failure 93.83 11.81 94 94059 198949 63195920
Normal newborn 93.16 11.81 86 94067 8255 63386614
Urinary incontinence 91.86 11.81 168 93985 31846 63363023
Disease progression 91.12 11.81 34 94119 122724 63272145
Folliculitis 90.69 11.81 3 94150 70314 63324555
Depressed mood 88.81 11.81 189 93964 40002 63354867
Obsessive-compulsive disorder 88.62 11.81 62 94091 3998 63390871
Obesity 86.98 11.81 158 93995 29794 63365075
Rabbit syndrome 85.64 11.81 28 94125 304 63394565
Apathy 83.68 11.81 83 94070 8711 63386158
Substance abuse 83.61 11.81 64 94089 4743 63390126
Disturbance in attention 82.55 11.81 178 93975 38011 63356858
Disinhibition 81.32 11.81 35 94118 848 63394021
Thermal burn 80.79 11.81 69 94084 5977 63388892
Muscle twitching 80.36 11.81 121 94032 19547 63375322
Muscle injury 80.20 11.81 4 94149 65341 63329528
Gastrointestinal disorder 79.55 11.81 48 94105 131191 63263678
Sinus tachycardia 79.52 11.81 135 94018 24133 63370736
Increased appetite 79.15 11.81 84 94069 9546 63385323
Seizure 78.72 11.81 397 93756 132237 63262632
Malignant neoplasm progression 77.56 11.81 14 94139 82107 63312762
Gaze palsy 76.95 11.81 39 94114 1381 63393488
Osteoarthritis 76.70 11.81 23 94130 95320 63299549
Off label use 76.32 11.81 1413 92740 673049 62721820
Pain in extremity 76.30 11.81 245 93908 331241 63063628
Premature delivery 75.87 11.81 150 94003 30131 63364738
Prescribed overdose 74.76 11.81 160 93993 33993 63360876
Hyperphagia 74.13 11.81 41 94112 1738 63393131
Arthritis 73.68 11.81 40 94113 115881 63278988
Dysarthria 73.52 11.81 182 93971 42529 63352340
General physical health deterioration 73.14 11.81 116 94037 201286 63193583
Back pain 72.78 11.81 179 93974 263966 63130903
Mobility decreased 72.47 11.81 45 94108 121114 63273755
Urinary retention 72.22 11.81 147 94006 30154 63364715
Psoriatic arthropathy 71.96 11.81 23 94130 91497 63303372
Affective disorder 71.83 11.81 65 94088 6081 63388788
Irritable bowel syndrome 71.74 11.81 17 94136 82395 63312474
Bipolar I disorder 71.63 11.81 41 94112 1858 63393011
Abortion induced 71.48 11.81 82 94071 10160 63384709
Insomnia 70.38 11.81 553 93600 214699 63180170
Mutism 69.11 11.81 38 94115 1592 63393277
Abortion 68.63 11.81 44 94109 2452 63392417
Symptom recurrence 68.06 11.81 39 94114 1771 63393098
Stupor 68.03 11.81 54 94099 4221 63390648
Nausea 67.48 11.81 879 93274 853592 62541277
Vertigo 66.66 11.81 218 93935 59669 63335200
Eosinophil count decreased 66.22 11.81 41 94112 2149 63392720
Urticaria 65.56 11.81 90 94063 165712 63229157
Hallucination, visual 65.42 11.81 109 94044 19189 63375680
Gambling 64.48 11.81 21 94132 225 63394644
Refusal of examination 64.23 11.81 20 94133 183 63394686
Wound 64.17 11.81 89 94064 163174 63231695
Euphoric mood 63.73 11.81 55 94098 4832 63390037
Pregnancy on contraceptive 62.45 11.81 32 94121 1160 63393709
Hypertonia 62.12 11.81 53 94100 4584 63390285
Altered state of consciousness 62.03 11.81 124 94029 25106 63369763
Anger 61.72 11.81 84 94069 12372 63382497
Musculoskeletal pain 61.38 11.81 30 94123 92247 63302622
Bradyphrenia 61.15 11.81 63 94090 6917 63387952
Hypothermia 60.46 11.81 87 94066 13494 63381375
Abdominal pain 60.03 11.81 228 93925 293228 63101641
Neuropathy peripheral 59.10 11.81 49 94104 113618 63281251
Libido increased 58.81 11.81 32 94121 1313 63393556
Rhabdomyolysis 58.21 11.81 170 93983 43781 63351088
Depressive symptom 57.25 11.81 48 94105 4054 63390815
Pyrexia 57.09 11.81 436 93717 470042 62924827
Exposure during pregnancy 56.08 11.81 409 93744 155138 63239731
Compulsive sexual behaviour 56.01 11.81 14 94139 50 63394819
Herpes zoster 54.55 11.81 27 94126 82435 63312434
Trimethylaminuria 54.55 11.81 17 94136 156 63394713
Flat affect 53.87 11.81 31 94122 1419 63393450
Ill-defined disorder 53.74 11.81 27 94126 81728 63313141
Soliloquy 52.47 11.81 18 94135 229 63394640
Abdominal pain upper 52.18 11.81 146 94007 206298 63188571
Inappropriate affect 52.16 11.81 26 94127 888 63393981
Thrombocytopenia 52.13 11.81 90 94063 151067 63243802
Hallucination, olfactory 51.23 11.81 18 94135 247 63394622
Personality change due to a general medical condition 51.00 11.81 17 94136 197 63394672
Memory impairment 50.95 11.81 296 93857 103962 63290907
Enuresis 50.88 11.81 37 94116 2536 63392333
Bruxism 50.75 11.81 42 94111 3483 63391386
Binge eating 50.70 11.81 21 94132 461 63394408
Affect lability 50.47 11.81 72 94081 11079 63383790
C-reactive protein abnormal 50.30 11.81 5 94148 46091 63348778
Erythema 50.03 11.81 117 94036 175634 63219235
Tic 49.91 11.81 30 94123 1490 63393379
Rhesus incompatibility 49.82 11.81 14 94139 86 63394783
Decreased appetite 48.81 11.81 199 93954 250853 63144016
Right ventricular false tendon 48.24 11.81 10 94143 10 63394859
Live birth 48.16 11.81 113 94040 25517 63369352
Restless legs syndrome 47.88 11.81 93 94060 18438 63376431
Threatened labour 47.87 11.81 24 94129 830 63394039
Cardiac failure congestive 47.86 11.81 40 94113 92393 63302476
Bankruptcy 47.66 11.81 11 94142 25 63394844
Knee arthroplasty 47.53 11.81 11 94142 54195 63340674
Wheezing 47.52 11.81 43 94110 95552 63299317
Coma 47.22 11.81 205 93948 64159 63330710
Mood swings 46.44 11.81 91 94062 18157 63376712
Suicidal behaviour 45.60 11.81 35 94118 2604 63392265
Self-injurious ideation 45.37 11.81 35 94118 2624 63392245
Pleurothotonus 45.27 11.81 27 94126 1322 63393547
Meconium aspiration syndrome 45.25 11.81 10 94143 17 63394852
Sepsis 44.34 11.81 101 94052 153022 63241847
Drug screen false positive 44.20 11.81 23 94130 861 63394008
Blunted affect 43.82 11.81 16 94137 247 63394622
Hypokinesia 43.65 11.81 76 94077 13860 63381009
Parkinsonian rest tremor 43.62 11.81 13 94140 101 63394768
Slow response to stimuli 43.59 11.81 24 94129 1008 63393861
Atrial fibrillation 43.44 11.81 66 94087 116570 63278299
Contusion 43.42 11.81 99 94054 149945 63244924
Antipsychotic drug level above therapeutic 43.36 11.81 24 94129 1019 63393850
Hospitalisation 43.17 11.81 244 93909 84837 63310032
Psychotic behaviour 43.14 11.81 20 94133 580 63394289
Hip arthroplasty 43.13 11.81 9 94144 47637 63347232
Accidental exposure to product by child 42.98 11.81 25 94128 1168 63393701
Depressed level of consciousness 42.73 11.81 194 93959 61884 63332985
Parkinsonian gait 42.69 11.81 19 94134 500 63394369
Delirium 42.59 11.81 168 93985 50373 63344496
Psychomotor skills impaired 42.22 11.81 32 94121 2336 63392533
Asthenia 42.12 11.81 365 93788 383239 63011630
Platelet count decreased 42.02 11.81 67 94086 116055 63278814
Eye movement disorder 41.90 11.81 45 94108 5183 63389686
Newborn persistent pulmonary hypertension 41.78 11.81 15 94138 220 63394649
Behaviour disorder 41.71 11.81 36 94117 3163 63391706
Somnambulism 41.44 11.81 46 94107 5497 63389372
Dysphagia 41.02 11.81 248 93905 88337 63306532
Paradoxical drug reaction 41.01 11.81 40 94113 4112 63390757
Pleural effusion 40.57 11.81 47 94106 93163 63301706
Red blood cell sedimentation rate increased 40.46 11.81 8 94145 43974 63350895
Acute psychosis 40.40 11.81 32 94121 2493 63392376
Headache 40.26 11.81 679 93474 632562 62762307
Mucosal inflammation 40.21 11.81 10 94143 46918 63347951
Refusal of treatment by patient 40.04 11.81 45 94108 5452 63389417
Resting tremor 39.97 11.81 21 94132 802 63394067
Psychomotor retardation 39.58 11.81 38 94115 3832 63391037
Pulmonary fibrosis 39.33 11.81 6 94147 39803 63355066
Stereotypy 39.00 11.81 17 94136 425 63394444
Paraesthesia 38.92 11.81 112 94041 156854 63238015
Oropharyngeal spasm 38.81 11.81 15 94138 273 63394596
Acute kidney injury 38.42 11.81 231 93922 263184 63131685
Ascites 38.33 11.81 7 94146 40721 63354148
Generalised tonic-clonic seizure 38.19 11.81 112 94041 28904 63365965
Death 37.72 11.81 364 93789 374017 63020852
Lactation disorder 37.70 11.81 16 94137 374 63394495
Blood triglycerides increased 37.69 11.81 67 94086 12421 63382448
Speech disorder 37.48 11.81 139 94014 40490 63354379
Skin ulcer 37.22 11.81 9 94144 43036 63351833
Alice in wonderland syndrome 37.20 11.81 9 94144 27 63394842
Productive cough 37.06 11.81 24 94129 63184 63331685
Dyslipidaemia 36.84 11.81 50 94103 7343 63387526
Colitis 36.74 11.81 13 94140 48515 63346354
Inappropriate schedule of product administration 36.67 11.81 272 93881 103693 63291176
Myoclonus 36.65 11.81 76 94077 15792 63379077
Homicidal ideation 36.49 11.81 26 94127 1726 63393143
Eosinophilic myocarditis 36.46 11.81 18 94135 602 63394267
Gastrointestinal haemorrhage 36.35 11.81 40 94113 81136 63313733
Conversion disorder 36.33 11.81 26 94127 1738 63393131
Withdrawal syndrome 36.31 11.81 87 94066 19910 63374959
Poisoning deliberate 36.21 11.81 62 94091 11156 63383713
Injection site erythema 36.13 11.81 42 94111 83132 63311737
Bone marrow oedema syndrome 36.04 11.81 9 94144 32 63394837
Intentional product use issue 35.70 11.81 86 94067 127806 63267063
Hepatotoxicity 35.66 11.81 6 94147 37035 63357834
Miosis 35.54 11.81 49 94104 7304 63387565
Inflammation 35.25 11.81 42 94111 82231 63312638
Product administered to patient of inappropriate age 35.15 11.81 33 94120 3235 63391634
Tachyphrenia 34.79 11.81 23 94130 1351 63393518
Negative symptoms in schizophrenia 34.19 11.81 11 94142 113 63394756
Joint range of motion decreased 34.15 11.81 4 94149 32424 63362445
Abulia 34.11 11.81 16 94137 477 63394392
Vomiting 33.95 11.81 605 93548 559012 62835857
Dyspnoea exertional 33.88 11.81 24 94129 60278 63334591
Electroencephalogram abnormal 33.72 11.81 34 94119 3638 63391231
Morbid thoughts 33.44 11.81 17 94136 606 63394263
Bundle branch block right 33.18 11.81 39 94114 4959 63389910
Cognitive disorder 33.03 11.81 167 93986 55648 63339221
Loss of consciousness 32.97 11.81 293 93860 117828 63277041
Neonatal hypotension 32.96 11.81 11 94142 128 63394741
Upper respiratory tract infection 32.95 11.81 44 94109 82003 63312866
Toxicity to various agents 32.82 11.81 532 93621 246718 63148151
Neuropsychiatric symptoms 32.72 11.81 18 94135 755 63394114
Antipsychotic drug level decreased 32.53 11.81 14 94139 339 63394530
Fibromyalgia 32.43 11.81 43 94110 80377 63314492
Drug withdrawal syndrome 32.07 11.81 101 94052 27093 63367776
Plasma cell myeloma 32.06 11.81 7 94146 35898 63358971
Bradykinesia 32.00 11.81 39 94114 5149 63389720
Intellectual disability 32.00 11.81 20 94133 1066 63393803
Osteoporosis 31.98 11.81 23 94130 57315 63337554
COVID-19 31.61 11.81 76 94077 113027 63281842
Crying 31.59 11.81 91 94062 23252 63371617
Melaena 31.36 11.81 4 94149 30361 63364508
Osteonecrosis of jaw 31.05 11.81 7 94146 35116 63359753
Birdshot chorioretinopathy 31.02 11.81 9 94144 63 63394806
Diverticulitis 30.98 11.81 10 94143 39547 63355322
Soft tissue injury 30.96 11.81 23 94130 1629 63393240
Breast feeding 30.83 11.81 18 94135 847 63394022
Septic shock 30.76 11.81 32 94121 66597 63328272
Sedation complication 30.52 11.81 65 94088 13757 63381112
Tachycardia 30.40 11.81 288 93865 117868 63277001
Liver injury 30.34 11.81 27 94126 60493 63334376
Personal relationship issue 30.30 11.81 9 94144 69 63394800
Disease recurrence 30.25 11.81 101 94052 27929 63366940
Multiple organ dysfunction syndrome 30.07 11.81 24 94129 56728 63338141
Sexually inappropriate behaviour 29.99 11.81 10 94143 116 63394753
Target skin lesion 29.99 11.81 10 94143 116 63394753
Breech presentation 29.96 11.81 20 94133 1194 63393675
Pancytopenia 29.65 11.81 62 94091 96871 63297998
Reduced facial expression 29.51 11.81 24 94129 1942 63392927
Nuchal rigidity 29.48 11.81 16 94137 653 63394216
Rebound psychosis 29.15 11.81 11 94142 187 63394682
Neoplasm progression 28.90 11.81 9 94144 36419 63358450
Trismus 28.63 11.81 32 94121 3853 63391016
Polyuria 28.62 11.81 48 94105 8494 63386375
Hypercalcaemia 28.60 11.81 4 94149 28318 63366551
Sinus rhythm 28.38 11.81 17 94136 839 63394030
Hypoventilation neonatal 28.23 11.81 7 94146 24 63394845
Epistaxis 28.20 11.81 40 94113 72685 63322184
Major depression 28.13 11.81 46 94107 7972 63386897
Myocarditis 28.13 11.81 53 94100 10272 63384597
Injection site pruritus 28.03 11.81 16 94137 45100 63349769
Grandiosity 27.98 11.81 12 94141 288 63394581
Megacolon 27.95 11.81 23 94130 1892 63392977
Compulsive hoarding 27.95 11.81 8 94145 53 63394816
Persistent depressive disorder 27.61 11.81 18 94135 1032 63393837
Oropharyngeal pain 27.60 11.81 62 94091 94425 63300444
Ideas of reference 27.26 11.81 9 94144 101 63394768
Haemoglobin decreased 27.21 11.81 117 94036 145368 63249501
Fluid retention 27.17 11.81 29 94124 59657 63335212
Chemical burn 26.98 11.81 13 94140 412 63394457
Neutrophil count increased 26.94 11.81 69 94084 16458 63378411
Agitation neonatal 26.93 11.81 14 94139 523 63394346
Dependent personality disorder 26.86 11.81 8 94145 62 63394807
Divorced 26.86 11.81 6 94147 11 63394858
Hereditary ataxia 26.81 11.81 7 94146 31 63394838
Premature labour 26.69 11.81 58 94095 12446 63382423
Uterine dilation and curettage 26.63 11.81 17 94136 940 63393929
Nephrogenic diabetes insipidus 26.60 11.81 17 94136 942 63393927
Pulmonary artery stenosis congenital 26.54 11.81 11 94142 242 63394627
Blood pressure systolic increased 26.45 11.81 19 94134 47378 63347491
Distractibility 26.44 11.81 13 94140 431 63394438
Selective eating disorder 26.37 11.81 23 94130 2049 63392820
Post-traumatic neck syndrome 26.35 11.81 23 94130 2051 63392818
Product substitution issue 26.30 11.81 67 94086 15929 63378940
Granulocytopenia 26.23 11.81 37 94116 5635 63389234
Postural tremor 26.18 11.81 12 94141 339 63394530
Nightmare 26.14 11.81 75 94078 19119 63375750
Chorioretinopathy 26.11 11.81 16 94137 823 63394046
Dyspepsia 26 11.81 72 94081 102124 63292745
Coronary artery disease 25.69 11.81 8 94145 32369 63362500
Femur fracture 25.67 11.81 15 94138 41741 63353128
Poor feeding infant 25.57 11.81 12 94141 358 63394511
Torticollis 25.55 11.81 22 94131 1927 63392942
Bone pain 25.49 11.81 26 94127 54615 63340254
Cardio-respiratory arrest 25.34 11.81 164 93989 59795 63335074
Syringe issue 25.32 11.81 26 94127 2843 63392026
Suspiciousness 25.30 11.81 12 94141 367 63394502
Chest pain 25.24 11.81 202 93951 215757 63179112
Accommodation disorder 25.24 11.81 12 94141 369 63394500
Movement disorder 25.13 11.81 80 94073 21581 63373288
Drug monitoring procedure not performed 25.09 11.81 14 94139 604 63394265
Apraxia 24.78 11.81 21 94132 1800 63393069
Physical assault 24.71 11.81 16 94137 907 63393962
Oromandibular dystonia 24.33 11.81 13 94140 514 63394355
Renal failure 24.28 11.81 91 94062 117561 63277308
Blood prolactin decreased 24.25 11.81 7 94146 48 63394821
Negativism 24.21 11.81 12 94141 405 63394464
Night sweats 24.20 11.81 22 94131 48792 63346077
Gynaecomastia 23.96 11.81 10 94143 224 63394645
Water intoxication 23.94 11.81 12 94141 415 63394454
Injection site reaction 23.89 11.81 31 94122 58493 63336376
Dysphoria 23.86 11.81 33 94120 4933 63389936
Microphthalmos 23.85 11.81 9 94144 153 63394716
Verbal abuse 23.82 11.81 8 94145 95 63394774
Eating disorder 23.70 11.81 72 94081 18944 63375925
Vision blurred 23.61 11.81 224 93929 91700 63303169
Drug effective for unapproved indication 23.59 11.81 27 94126 3337 63391532
Hyperhidrosis 23.48 11.81 254 93899 107582 63287287
Delusion of reference 23.45 11.81 8 94145 100 63394769
Biliary tract infection 23.43 11.81 14 94139 688 63394181
Facial nerve disorder 23.40 11.81 13 94140 556 63394313
Body mass index decreased 23.24 11.81 12 94141 442 63394427
Blepharospasm 23.24 11.81 36 94117 5960 63388909
Anaphylactic reaction 23.10 11.81 39 94114 66061 63328808
Therapy cessation 23.09 11.81 98 94055 30359 63364510
Hypoxia 23.07 11.81 33 94120 59759 63335110
Gastric ulcer 22.90 11.81 4 94149 24033 63370836
Food craving 22.84 11.81 19 94134 1587 63393282
Cholestasis of pregnancy 22.83 11.81 17 94136 1208 63393661
Therapy non-responder 22.83 11.81 49 94104 75852 63319017
Sternal fracture 22.80 11.81 22 94131 2232 63392637
Cholangitis infective 22.64 11.81 11 94142 355 63394514
Emotional distress 22.60 11.81 102 94051 32447 63362422
Floppy iris syndrome 22.49 11.81 8 94145 114 63394755
Bronchitis 22.43 11.81 102 94051 124833 63270036
Hypersomnia 22.16 11.81 68 94085 17987 63376882
Autonomic nervous system imbalance 22.13 11.81 24 94129 2794 63392075
Hyperreflexia 22.12 11.81 35 94118 5899 63388970
Electrocardiogram QRS complex prolonged 22.11 11.81 35 94118 5903 63388966
Choroiditis 22.10 11.81 9 94144 189 63394680
Retinal coloboma 22.06 11.81 6 94147 32 63394837
Shoplifting 22.06 11.81 4 94149 0 63394869
Cerebral haemorrhage 21.98 11.81 9 94144 30720 63364149
Urinary tract infection 21.95 11.81 269 93884 264415 63130454
Foot deformity 21.89 11.81 7 94146 27846 63367023
Oedema 21.82 11.81 73 94080 97549 63297320
Bursitis 21.80 11.81 14 94139 37027 63357842
Intention tremor 21.77 11.81 11 94142 387 63394482
Premature baby 21.75 11.81 74 94079 20661 63374208
Morning sickness 21.73 11.81 14 94139 787 63394082
Weight decreased 21.59 11.81 285 93868 276513 63118356
Full blood count abnormal 21.56 11.81 10 94143 31707 63363162
Palmar-plantar erythrodysaesthesia syndrome 21.56 11.81 4 94149 23011 63371858
Hypoprolactinaemia 21.48 11.81 5 94148 12 63394857
Myocarditis septic 21.47 11.81 6 94147 36 63394833
Dissociation 21.44 11.81 24 94129 2895 63391974
Full blood count decreased 21.43 11.81 6 94147 26018 63368851
Dry skin 21.36 11.81 32 94121 56855 63338014
Ataxia 21.30 11.81 60 94093 15135 63379734
Macular degeneration 21.26 11.81 5 94148 24371 63370498
Haemoptysis 21.23 11.81 8 94145 28718 63366151
Haematochezia 21.21 11.81 29 94124 53515 63341354
Pneumonitis 21.16 11.81 13 94140 35209 63359660
No adverse event 21.16 11.81 119 94034 41286 63353583
Malaise 21.14 11.81 463 93690 415491 62979378
Anterograde amnesia 21.14 11.81 12 94141 535 63394334
Monocyte count increased 21.08 11.81 39 94114 7454 63387415
Cytomegalovirus infection 21.06 11.81 3 94150 20949 63373920
Rectal haemorrhage 21.03 11.81 25 94128 49005 63345864
Post-traumatic stress disorder 21.02 11.81 32 94121 5219 63389650
Sleep-related eating disorder 20.95 11.81 14 94139 837 63394032
Decreased interest 20.95 11.81 25 94128 3229 63391640
Bladder dilatation 20.86 11.81 14 94139 843 63394026
Iris coloboma 20.80 11.81 6 94147 41 63394828
Inappropriate antidiuretic hormone secretion 20.65 11.81 60 94093 15402 63379467
International normalised ratio abnormal 20.64 11.81 25 94128 3279 63391590
Abortion threatened 20.64 11.81 12 94141 560 63394309
Meningitis streptococcal 20.53 11.81 8 94145 149 63394720
Dementia with Lewy bodies 20.43 11.81 10 94143 328 63394541
Basal cell carcinoma 20.34 11.81 8 94145 27983 63366886
Obsessive thoughts 20.28 11.81 12 94141 579 63394290
Drug ineffective for unapproved indication 20.21 11.81 102 94051 33961 63360908
Immunodeficiency 20.13 11.81 3 94150 20251 63374618
Chills 20.09 11.81 93 94060 113285 63281584
Emotional poverty 19.86 11.81 10 94143 349 63394520
Lung disorder 19.74 11.81 39 94114 62222 63332647
Diabetic hyperosmolar coma 19.58 11.81 10 94143 360 63394509
Protrusion tongue 19.58 11.81 10 94143 360 63394509
Fear of weight gain 19.56 11.81 5 94148 20 63394849
Drowning 19.55 11.81 11 94142 482 63394387
Intermenstrual bleeding 19.53 11.81 39 94114 7887 63386982
Blood pressure fluctuation 19.46 11.81 24 94129 46293 63348576
Asocial behaviour 19.36 11.81 5 94148 21 63394848
Menstruation irregular 19.14 11.81 36 94117 6968 63387901
Polydipsia 19.14 11.81 25 94128 3539 63391330
Sleep deficit 19.12 11.81 12 94141 644 63394225
Merycism 19.07 11.81 9 94144 272 63394597
Hunger 19.06 11.81 31 94122 5348 63389521
Twin pregnancy 19.06 11.81 15 94138 1158 63393711
Pulmonary mass 19.00 11.81 5 94148 22591 63372278
Polyhydramnios 19.00 11.81 20 94133 2251 63392618
Hip fracture 18.97 11.81 10 94143 29464 63365405
Hyperkalaemia 18.92 11.81 32 94121 54171 63340698
Akinesia 18.91 11.81 17 94136 1576 63393293
Delusional disorder, unspecified type 18.91 11.81 10 94143 387 63394482
Suicide threat 18.82 11.81 5 94148 24 63394845
Cataract 18.73 11.81 35 94118 57018 63337851
Malignant catatonia 18.66 11.81 8 94145 192 63394677
Genitourinary symptom 18.62 11.81 6 94147 62 63394807
Grip strength decreased 18.61 11.81 5 94148 22282 63372587
Obstructive airways disorder 18.55 11.81 4 94149 20695 63374174
Dehydration 18.52 11.81 166 93987 173188 63221681
Rash pruritic 18.49 11.81 38 94115 59761 63335108
Metastases to liver 18.47 11.81 6 94147 23633 63371236
Dyskinesia oesophageal 18.41 11.81 4 94149 6 63394863
Rhinorrhoea 18.37 11.81 44 94109 65533 63329336
Gastritis 18.27 11.81 17 94136 37286 63357583
Congenital ureteric anomaly 18.12 11.81 6 94147 68 63394801
Cross sensitivity reaction 18.02 11.81 19 94134 2143 63392726
Pregnancy with implant contraceptive 17.92 11.81 21 94132 2662 63392207
Decreased activity 17.91 11.81 33 94120 6287 63388582
Chest discomfort 17.87 11.81 93 94060 109876 63284993
Waxy flexibility 17.74 11.81 7 94146 135 63394734
Homeless 17.73 11.81 6 94147 73 63394796
Negative thoughts 17.58 11.81 13 94140 914 63393955
Theft 17.51 11.81 6 94147 76 63394793
Breath odour 17.50 11.81 15 94138 1305 63393564
Hypertonic bladder 17.48 11.81 24 94129 3564 63391305
Bone disorder 17.41 11.81 5 94148 21321 63373548
Right ventricular systolic pressure decreased 17.36 11.81 5 94148 34 63394835
Nodule 17.03 11.81 5 94148 21021 63373848
Metastases to bone 17.02 11.81 5 94148 21014 63373855
Developmental hip dysplasia 17.00 11.81 15 94138 1357 63393512
Localised infection 17.00 11.81 12 94141 30198 63364671
Emotional disorder 16.99 11.81 51 94102 13328 63381541
Joint hyperextension 16.80 11.81 9 94144 358 63394511
Transient aphasia 16.76 11.81 5 94148 39 63394830
Disorientation 16.72 11.81 108 94045 39344 63355525
Ventricular septal defect 16.57 11.81 26 94127 4352 63390517
Oral herpes 16.55 11.81 9 94144 26065 63368804
Noninfective encephalomyelitis 16.55 11.81 3 94150 0 63394869
Schizoaffective disorder depressive type 16.55 11.81 3 94150 0 63394869
Pyromania 16.55 11.81 3 94150 0 63394869
Acute myocardial infarction 16.50 11.81 14 94139 32110 63362759
Cardiac failure 16.47 11.81 72 94081 89070 63305799
Type 1 diabetes mellitus 16.46 11.81 24 94129 3766 63391103
Injection site bruising 16.30 11.81 23 94130 41887 63352982
Joint stiffness 16.26 11.81 23 94130 41846 63353023
Pseudodementia 16.18 11.81 6 94147 97 63394772
Trisomy 21 16.18 11.81 9 94144 386 63394483
Screaming 16.16 11.81 22 94131 3240 63391629
Hypocalcaemia 16.07 11.81 14 94139 31699 63363170
Bone marrow failure 16.01 11.81 12 94141 29278 63365591
Dysbiosis 15.62 11.81 12 94141 894 63393975
Blood cholesterol increased 15.58 11.81 79 94074 93953 63300916
Non-cardiogenic pulmonary oedema 15.57 11.81 11 94142 720 63394149
Diabetic ketoacidosis 15.56 11.81 66 94087 20439 63374430
Oxygen saturation decreased 15.50 11.81 73 94080 88512 63306357
Osteopenia 15.50 11.81 5 94148 19780 63375089
Helplessness 15.46 11.81 8 94145 296 63394573
Fear 15.43 11.81 55 94098 15711 63379158
White blood cell count increased 15.41 11.81 124 94029 48437 63346432
Antipsychotic drug level below therapeutic 15.36 11.81 8 94145 300 63394569
Poisoning 15.35 11.81 50 94103 13650 63381219
Lung neoplasm malignant 15.31 11.81 5 94148 19628 63375241
Hypothyroidism 15.28 11.81 112 94041 42520 63352349
Hyponatriuria 15.27 11.81 4 94149 18 63394851
Pseudomyopia 15.23 11.81 5 94148 55 63394814
Urine amphetamine positive 15.23 11.81 5 94148 55 63394814
Swelling face 15.21 11.81 46 94107 63429 63331440
Grimacing 15.20 11.81 9 94144 435 63394434
Haematocrit increased 15.19 11.81 18 94135 2308 63392561
Feeling of despair 15.11 11.81 18 94135 2321 63392548
Affective ambivalence 15.09 11.81 4 94149 19 63394850
Inability to afford medication 15.06 11.81 18 94135 2329 63392540
Sleep disorder 15.02 11.81 186 93967 81380 63313489
Urate nephropathy 14.96 11.81 6 94147 121 63394748
Creatinine renal clearance decreased 14.93 11.81 3 94150 16305 63378564
Injection site pain 14.88 11.81 122 94031 129678 63265191
Hemiparesis 14.83 11.81 8 94145 23274 63371595
Poor personal hygiene 14.80 11.81 8 94145 324 63394545
Hypernatraemia 14.79 11.81 34 94119 7575 63387294
Muscle tightness 14.78 11.81 45 94108 11855 63383014
Breast enlargement 14.75 11.81 15 94138 1621 63393248
Activation syndrome 14.73 11.81 7 94146 215 63394654
Bronchiectasis 14.71 11.81 3 94150 16139 63378730
Electroconvulsive therapy 14.69 11.81 5 94148 62 63394807
Cellulitis 14.66 11.81 67 94086 81891 63312978
Haematuria 14.62 11.81 13 94140 29144 63365725
Gastrointestinal lymphoma 14.62 11.81 5 94148 63 63394806
Fungal infection 14.57 11.81 20 94133 36854 63358015
Staphylococcal infection 14.57 11.81 108 94045 41148 63353721
Trichotillomania 14.47 11.81 6 94147 132 63394737
Disruptive mood dysregulation disorder 14.47 11.81 3 94150 3 63394866
Influenza 14.46 11.81 98 94055 108624 63286245
Drug tolerance decreased 14.44 11.81 4 94149 17469 63377400
Congenital hypothyroidism 14.43 11.81 7 94146 225 63394644
Hypoaesthesia 14.38 11.81 170 93983 168223 63226646
Convulsive threshold lowered 14.36 11.81 8 94145 344 63394525
Arachnoid cyst 14.32 11.81 7 94146 229 63394640
Echopraxia 14.31 11.81 4 94149 24 63394845
Pneumonia aspiration 14.30 11.81 94 94059 34446 63360423
Irregular sleep phase 14.17 11.81 4 94149 25 63394844
Immunodeficiency common variable 14.15 11.81 7 94146 235 63394634
Menstrual disorder 14.14 11.81 27 94126 5286 63389583
Asthma 14.13 11.81 121 94032 127440 63267429
Anhedonia 14.10 11.81 42 94111 10932 63383937
Bacillus infection 14.06 11.81 11 94142 842 63394027
Panic attack 14.05 11.81 68 94085 22263 63372606
Delusional perception 13.91 11.81 7 94146 244 63394625
Fibrin D dimer increased 13.91 11.81 26 94127 5008 63389861
Cast application 13.91 11.81 4 94149 27 63394842
Food refusal 13.89 11.81 8 94145 367 63394502
Peripheral venous disease 13.85 11.81 3 94150 15474 63379395
Delusion of grandeur 13.70 11.81 7 94146 252 63394617
Schizophreniform disorder 13.65 11.81 5 94148 78 63394791
Spasmodic dysphonia 13.59 11.81 5 94148 79 63394790
Haemorrhoids 13.55 11.81 8 94145 22142 63372727
Device related infection 13.55 11.81 9 94144 23383 63371486
Delusional disorder, erotomanic type 13.55 11.81 4 94149 30 63394839
Neonatal respiratory distress 13.50 11.81 8 94145 387 63394482
Laboratory test abnormal 13.49 11.81 12 94141 26900 63367969
Diabetic coma 13.48 11.81 10 94143 707 63394162
Concussion 13.45 11.81 37 94116 9207 63385662
Electrocardiogram PR prolongation 13.39 11.81 10 94143 714 63394155
Hypotonia 13.35 11.81 37 94116 9248 63385621
Paralogism 13.32 11.81 4 94149 32 63394837
Violence-related symptom 13.26 11.81 8 94145 400 63394469
Adrenal insufficiency 13.22 11.81 5 94148 17910 63376959
Heart rate decreased 13.22 11.81 30 94123 45530 63349339
Paraesthesia oral 13.20 11.81 6 94147 19250 63375619
Blood folate decreased 13.15 11.81 10 94143 734 63394135
Gestational hypertension 13.05 11.81 17 94136 2400 63392469
Mean cell haemoglobin concentration decreased 13.05 11.81 21 94132 3591 63391278
Hypomagnesaemia 13.04 11.81 14 94139 28723 63366146
Staring 13.01 11.81 14 94139 1616 63393253
Induced labour 13.01 11.81 11 94142 940 63393929
Pulmonary oedema 12.98 11.81 40 94113 54833 63340036
Taciturnity 12.94 11.81 3 94150 7 63394862
Intrapartum haemorrhage 12.94 11.81 3 94150 7 63394862
Oral candidiasis 12.90 11.81 9 94144 22789 63372080
Atelectasis 12.81 11.81 8 94145 21475 63373394
Neurological examination normal 12.81 11.81 4 94149 37 63394832
Respiratory disorder 12.80 11.81 24 94129 39058 63355811
Hypoglycaemia neonatal 12.77 11.81 11 94142 964 63393905
Nasal congestion 12.76 11.81 52 94101 65608 63329261
Wound infection 12.73 11.81 8 94145 21402 63373467
Polyneuropathy 12.71 11.81 3 94150 14586 63380283
Foetal malnutrition 12.69 11.81 5 94148 96 63394773
Epilepsy 12.67 11.81 76 94077 26989 63367880
Ulcer 12.66 11.81 12 94141 26095 63368774
Hypersomnia-bulimia syndrome 12.66 11.81 3 94150 8 63394861
Pseudomembranous colitis 12.50 11.81 19 94134 3093 63391776
Subdural haematoma 12.38 11.81 3 94150 14325 63380544
Patient dissatisfaction with treatment 12.37 11.81 5 94148 103 63394766
Abnormal dreams 12.35 11.81 39 94114 10477 63384392
Rash erythematous 12.32 11.81 28 94125 42482 63352387
Axonal neuropathy 12.32 11.81 11 94142 1011 63393858
Product availability issue 12.29 11.81 22 94131 4099 63390770
Respiratory tract infection 12.29 11.81 27 94126 41456 63353413
COVID-19 pneumonia 12.23 11.81 3 94150 14206 63380663
Osteonecrosis 12.22 11.81 11 94142 24519 63370350
Product administered by wrong person 12.16 11.81 3 94150 10 63394859
Acute hepatic failure 12.12 11.81 6 94147 18321 63376548
Female sexual dysfunction 12.11 11.81 4 94149 45 63394824
Blood potassium increased 12.10 11.81 6 94147 18303 63376566
Panic reaction 12.09 11.81 22 94131 4152 63390717
Confusional arousal 12.06 11.81 6 94147 204 63394665
Abdominal distension 12.06 11.81 77 94076 86538 63308331
Ear infection 12.06 11.81 24 94129 38189 63356680
Large for dates baby 12.02 11.81 8 94145 475 63394394
Injection site haemorrhage 12.00 11.81 11 94142 24303 63370566
Chronic obstructive pulmonary disease 11.96 11.81 50 94103 62636 63332233
Lip dry 11.96 11.81 4 94149 15466 63379403
Adrenal cyst 11.94 11.81 5 94148 113 63394756
Sleep apnoea syndrome 11.89 11.81 79 94074 29054 63365815
Blood glucose fluctuation 11.86 11.81 23 94130 4553 63390316
Meningism 11.84 11.81 8 94145 487 63394382
Respiratory arrest 11.84 11.81 86 94067 32559 63362310
Muscle spasticity 11.82 11.81 9 94144 21785 63373084

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 1319.28 14.07 523 68355 7586 34880467
Neuroleptic malignant syndrome 1205.51 14.07 624 68254 17310 34870743
Psychotic disorder 1120.96 14.07 661 68217 23791 34864262
Tardive dyskinesia 915.71 14.07 366 68512 5424 34882629
Extrapyramidal disorder 905.34 14.07 462 68416 12418 34875635
Dystonia 817.79 14.07 408 68470 10437 34877616
Sedation 801.23 14.07 505 68373 20501 34867552
Weight increased 615.96 14.07 834 68044 92199 34795854
Delusion 608.76 14.07 353 68525 12282 34875771
Parkinsonism 604.14 14.07 303 68575 7835 34880218
Suicide attempt 597.74 14.07 544 68334 38572 34849481
Hallucination, auditory 582.26 14.07 336 68542 11581 34876472
Dyskinesia 474.25 14.07 376 68502 22037 34866016
Suicidal ideation 457.92 14.07 477 68401 39911 34848142
Product use in unapproved indication 444.71 14.07 815 68063 116684 34771369
Aggression 441.41 14.07 460 68418 38504 34849549
Gambling disorder 434.94 14.07 152 68726 1508 34886545
Schizophrenia 425.04 14.07 245 68633 8421 34879632
Treatment noncompliance 356.94 14.07 353 68525 27747 34860306
Mania 348.30 14.07 223 68655 9288 34878765
Obsessive-compulsive disorder 340.50 14.07 182 68696 5382 34882671
Agitation 335.22 14.07 485 68393 56914 34831139
Sexual dysfunction 327.34 14.07 185 68693 6118 34881935
Psychotic symptom 317.10 14.07 122 68756 1621 34886432
Hyperprolactinaemia 280.70 14.07 109 68769 1487 34886566
Blood creatine phosphokinase increased 279.47 14.07 391 68487 44466 34843587
Salivary hypersecretion 275.90 14.07 186 68692 8458 34879595
Catatonia 273.20 14.07 152 68726 4873 34883180
Restlessness 272.72 14.07 292 68586 25190 34862863
Blood prolactin abnormal 270.36 14.07 93 68785 876 34887177
Antipsychotic drug level below therapeutic 240.90 14.07 112 68766 2435 34885618
Febrile neutropenia 237.59 14.07 7 68871 136842 34751211
Irritability 236.60 14.07 267 68611 24423 34863630
Disinhibition 233.15 14.07 118 68760 3108 34884945
Oculogyric crisis 232.56 14.07 95 68783 1491 34886562
Anaemia 220.72 14.07 92 68786 233243 34654810
Muscle rigidity 219.26 14.07 175 68703 10343 34877710
Dyspnoea 215.57 14.07 256 68622 376526 34511527
Diarrhoea 208.42 14.07 279 68599 389633 34498420
Increased appetite 206.87 14.07 147 68731 7282 34880771
Abnormal behaviour 205.89 14.07 250 68628 24719 34863334
Pneumonia 201.45 14.07 252 68626 362375 34525678
Emotional poverty 200.90 14.07 66 68812 532 34887521
Hypersexuality 200.54 14.07 84 68794 1409 34886644
Anosognosia 198.29 14.07 74 68804 899 34887154
Persecutory delusion 197.12 14.07 98 68780 2482 34885571
Anxiety 189.22 14.07 525 68353 98903 34789150
Euphoric mood 188.71 14.07 125 68753 5516 34882537
Obesity 188.47 14.07 175 68703 12703 34875350
Priapism 187.55 14.07 119 68759 4875 34883178
Drug ineffective 182.66 14.07 1526 67352 455225 34432828
Paranoia 180.50 14.07 166 68712 11902 34876151
Therapeutic product effect variable 172.14 14.07 88 68790 2368 34885685
Social avoidant behaviour 168.73 14.07 94 68784 3020 34885033
Somnolence 164.48 14.07 537 68341 110579 34777474
Foetal exposure during pregnancy 161.32 14.07 278 68600 37823 34850230
Disturbance in social behaviour 155.45 14.07 75 68803 1776 34886277
Metabolic disorder 153.26 14.07 99 68779 4184 34883869
Tremor 153.04 14.07 432 68446 82155 34805898
Prescribed overdose 148.73 14.07 141 68737 10506 34877547
Psychiatric symptom 147.83 14.07 90 68788 3423 34884630
Malignant neoplasm progression 144.21 14.07 7 68871 88039 34800014
Intentional self-injury 144.11 14.07 156 68722 13615 34874438
Apathy 143.75 14.07 115 68763 6817 34881236
Psychomotor hyperactivity 141.26 14.07 131 68747 9491 34878562
Acute kidney injury 137.04 14.07 245 68633 304743 34583310
Psychiatric decompensation 133.32 14.07 79 68799 2858 34885195
Tic 130.64 14.07 69 68809 1989 34886064
Thinking abnormal 129.80 14.07 103 68775 6034 34882019
Mental impairment 129.73 14.07 129 68749 10193 34877860
Serotonin syndrome 128.90 14.07 177 68701 19756 34868297
Homicidal ideation 121.37 14.07 72 68806 2610 34885443
Sedation complication 119.71 14.07 62 68816 1715 34886338
Underdose 118.52 14.07 141 68737 13639 34874414
Affective disorder 118.45 14.07 85 68793 4275 34883778
Sepsis 117.06 14.07 94 68784 166467 34721586
Hallucination 116.26 14.07 290 68588 51208 34836845
Delusional disorder, persecutory type 114.77 14.07 37 68841 279 34887774
Drooling 113.26 14.07 75 68803 3307 34884746
Cough 111.55 14.07 80 68798 150060 34737993
Arthralgia 110.94 14.07 103 68775 169938 34718115
Bruxism 109.65 14.07 58 68820 1677 34886376
Compulsive sexual behaviour 106.12 14.07 33 68845 218 34887835
Compulsive shopping 105.85 14.07 37 68841 367 34887686
Intentional overdose 102.87 14.07 250 68628 43424 34844629
Pain 102.45 14.07 153 68725 204522 34683531
Cogwheel rigidity 102.23 14.07 51 68827 1301 34886752
Hypomania 100.71 14.07 61 68817 2298 34885755
Myocarditis 99.99 14.07 129 68749 13553 34874500
Pyrexia 99.43 14.07 331 68547 332682 34555371
Insomnia 98.71 14.07 436 68442 103471 34784582
Death 98.01 14.07 428 68450 397621 34490432
Drug interaction 97.83 14.07 770 68108 225176 34662877
Schizoaffective disorder 97.23 14.07 49 68829 1278 34886775
Electrocardiogram QT prolonged 97.07 14.07 235 68643 40717 34847336
Disease progression 96.66 14.07 46 68832 108031 34780022
Asthenia 95.46 14.07 214 68664 245037 34643016
Torticollis 94.62 14.07 46 68832 1108 34886945
Pruritus 93.77 14.07 85 68793 141896 34746157
Prescribed underdose 89.64 14.07 99 68779 8834 34879219
Libido increased 88.57 14.07 40 68838 811 34887242
Rhabdomyolysis 88.07 14.07 315 68563 67848 34820205
Pleural effusion 87.45 14.07 26 68852 81520 34806533
Atrial fibrillation 87.29 14.07 68 68810 122325 34765728
Blood prolactin increased 86.91 14.07 50 68828 1710 34886343
General physical health deterioration 86.85 14.07 75 68803 128194 34759859
Loss of libido 86.44 14.07 57 68821 2495 34885558
Oedema peripheral 84.90 14.07 67 68811 119745 34768308
Oppositional defiant disorder 84.32 14.07 34 68844 515 34887538
Antipsychotic drug level increased 84.17 14.07 66 68812 3799 34884254
Infection 83.93 14.07 37 68841 90878 34797175
Economic problem 83.47 14.07 44 68834 1263 34886790
Hospitalisation 83.15 14.07 274 68604 56628 34831425
Delusion of grandeur 82.56 14.07 42 68836 1118 34886935
Anger 82.10 14.07 109 68769 11775 34876278
Hypotension 80.94 14.07 200 68678 221449 34666604
Mental disorder 80.72 14.07 123 68755 15086 34872967
Renal failure 79.45 14.07 84 68794 130473 34757580
Thrombocytopenia 78.91 14.07 116 68762 156131 34731922
Joint swelling 78.66 14.07 12 68866 59878 34828175
Pain in extremity 78.56 14.07 80 68798 126433 34761620
Trismus 77.96 14.07 53 68825 2442 34885611
Product administered to patient of inappropriate age 77.78 14.07 59 68819 3232 34884821
Ascites 75.29 14.07 4 68874 46567 34841486
Breech presentation 75.15 14.07 23 68855 143 34887910
Paradoxical drug reaction 74.65 14.07 58 68820 3293 34884760
Overdose 74.60 14.07 366 68512 90693 34797360
Abdominal pain 74.59 14.07 130 68748 163488 34724565
Gambling 74.32 14.07 24 68854 182 34887871
Gastrointestinal haemorrhage 74.12 14.07 41 68837 88436 34799617
Drug monitoring procedure incorrectly performed 73.97 14.07 25 68853 222 34887831
Interstitial lung disease 73.38 14.07 19 68859 65263 34822790
Antipsychotic drug level decreased 72.90 14.07 37 68841 980 34887073
Depression 70.29 14.07 377 68501 96721 34791332
Personality change 69.75 14.07 67 68811 5072 34882981
International normalised ratio increased 68.18 14.07 7 68871 47320 34840733
Back pain 67.97 14.07 84 68794 121705 34766348
Sleep disorder 66.86 14.07 174 68704 31514 34856539
Plasma cell myeloma 66.75 14.07 4 68874 42033 34846020
Infusion related reaction 66.63 14.07 12 68866 53045 34835008
Therapeutic product effect incomplete 66.48 14.07 235 68643 50306 34837747
Cardiac failure congestive 66.33 14.07 41 68837 83229 34804824
Hypothermia 65.82 14.07 93 68785 10655 34877398
Choreoathetosis 65.63 14.07 35 68843 1029 34887024
Decreased eye contact 63.64 14.07 27 68851 468 34887585
Refusal of treatment by patient 63.43 14.07 63 68815 4969 34883084
Tachycardia 63.30 14.07 332 68546 84440 34803613
Blood triglycerides increased 62.11 14.07 105 68773 14054 34873999
Victim of child abuse 61.46 14.07 32 68846 895 34887158
Blood prolactin decreased 61.15 14.07 22 68856 239 34887814
Nausea 59.53 14.07 409 68469 339499 34548554
Myocardial infarction 59.07 14.07 92 68786 120993 34767060
Completed suicide 58.52 14.07 362 68516 97806 34790247
Rash 56.78 14.07 236 68642 222516 34665537
Respiratory failure 56.36 14.07 79 68799 108493 34779560
Coronary artery disease 56.35 14.07 13 68865 48292 34839761
Septic shock 56.33 14.07 36 68842 71798 34816255
Tongue movement disturbance 55.23 14.07 17 68861 108 34887945
Antidepressant drug level above therapeutic 54.89 14.07 20 68858 226 34887827
Neutrophil count increased 54.87 14.07 111 68767 17035 34871018
Hyperkalaemia 54.11 14.07 35 68843 69354 34818699
Homosexuality 53.92 14.07 14 68864 42 34888011
Impulsive behaviour 53.85 14.07 40 68838 2122 34885931
Dystonic tremor 53.35 14.07 19 68859 200 34887853
Speech disorder 53.12 14.07 140 68738 25546 34862507
Dysarthria 53.05 14.07 170 68708 34612 34853441
Muscle twitching 52.84 14.07 82 68796 10216 34877837
Multiple organ dysfunction syndrome 52.73 14.07 44 68834 76522 34811531
Depressed mood 52.49 14.07 117 68761 19200 34868853
Prostate cancer 51.93 14.07 8 68870 39641 34848412
Pancytopenia 51.65 14.07 67 68811 95090 34792963
Bradykinesia 51.42 14.07 50 68828 3843 34884210
Fatigue 51.04 14.07 476 68402 370177 34517876
Mydriasis 50.95 14.07 67 68811 7170 34880883
Keratoconus 50.78 14.07 16 68862 111 34887942
Urticaria 50.66 14.07 30 68848 62347 34825706
Water intoxication 50.60 14.07 22 68856 406 34887647
Leukopenia 50.27 14.07 251 68627 62605 34825448
Analgesic drug level above therapeutic 50.20 14.07 20 68858 293 34887760
Neuropathy peripheral 50.14 14.07 54 68824 83209 34804844
Off label use 49.94 14.07 1128 67750 418396 34469657
Multiple drug therapy 49.03 14.07 22 68856 439 34887614
Self-injurious ideation 48.44 14.07 34 68844 1650 34886403
Sudden death 48.15 14.07 98 68780 15103 34872950
Affect lability 48.07 14.07 47 68831 3636 34884417
Lactic acidosis 47.93 14.07 6 68872 34766 34853287
Haematochezia 47.80 14.07 16 68862 46518 34841535
Rheumatoid arthritis 47.25 14.07 9 68869 38229 34849824
Sinus tachycardia 47.01 14.07 105 68773 17255 34870798
Anxiolytic therapy 46.99 14.07 13 68865 53 34888000
Epidural lipomatosis 46.92 14.07 28 68850 1026 34887027
Renal impairment 46.86 14.07 71 68807 94442 34793611
Haemoglobin decreased 46.37 14.07 106 68772 120666 34767387
Acute myocardial infarction 46.28 14.07 24 68854 53695 34834358
Exhibitionism 46.21 14.07 12 68866 36 34888017
Dyslipidaemia 46.16 14.07 65 68813 7423 34880630
Drug therapy enhancement 45.35 14.07 13 68865 62 34887991
Musculoskeletal pain 45.34 14.07 5 68873 31958 34856095
Wrong technique in product usage process 45.33 14.07 165 68713 35821 34852232
Blepharospasm 44.94 14.07 28 68850 1110 34886943
Cardiac failure 44.80 14.07 69 68809 91179 34796874
Hyperthermia 44.50 14.07 77 68801 10500 34877553
Disturbance in sexual arousal 44.40 14.07 15 68863 133 34887920
Colitis 44.35 14.07 10 68868 37740 34850313
Dyspnoea exertional 44.24 14.07 15 68863 43264 34844789
Paraphilia 44.20 14.07 13 68865 69 34887984
Oromandibular dystonia 44.20 14.07 21 68857 480 34887573
Hypoxia 44.04 14.07 27 68851 55068 34832985
Gynaecomastia 43.99 14.07 75 68803 10105 34877948
Urinary tract infection 43.80 14.07 61 68817 84020 34804033
Disturbance in attention 43.44 14.07 131 68747 25814 34862239
Stomatitis 43.00 14.07 15 68863 42499 34845554
Sinusitis 42.94 14.07 14 68864 41388 34846665
Crying 42.40 14.07 55 68823 5807 34882246
Melaena 42.31 14.07 9 68869 35371 34852682
Abdominal distension 42.30 14.07 32 68846 58460 34829593
Haematuria 42.20 14.07 23 68855 50043 34838010
Chills 42.01 14.07 59 68819 80984 34807069
Epistaxis 41.95 14.07 32 68846 58219 34829834
Chronic kidney disease 40.90 14.07 15 68863 41195 34846858
Erythema 40.90 14.07 70 68808 88710 34799343
Substance-induced psychotic disorder 40.72 14.07 31 68847 1707 34886346
Loss of employment 40.64 14.07 20 68858 495 34887558
Urinary incontinence 40.17 14.07 104 68774 18770 34869283
Electrocardiogram QT shortened 39.95 14.07 14 68864 140 34887913
Seizure 39.67 14.07 347 68531 104510 34783543
Tongue biting 39.55 14.07 24 68854 907 34887146
Wheezing 39.55 14.07 16 68862 41386 34846667
Bradyphrenia 39.45 14.07 48 68830 4750 34883303
Rebound effect 39.45 14.07 40 68838 3234 34884819
Leukaemia 39.41 14.07 47 68831 4556 34883497
Psychomotor retardation 39.32 14.07 42 68836 3608 34884445
Intentional product use issue 39.21 14.07 36 68842 59780 34828273
Bipolar disorder 39.14 14.07 42 68836 3627 34884426
Acute psychosis 39.11 14.07 31 68847 1812 34886241
Bankruptcy 39.07 14.07 9 68869 13 34888040
Hostility 38.98 14.07 23 68855 825 34887228
Exposure via breast milk 38.83 14.07 32 68846 1978 34886075
Diabetes mellitus 38.77 14.07 189 68689 46684 34841369
Head titubation 38.64 14.07 18 68860 393 34887660
Pneumonitis 37.79 14.07 10 68868 33868 34854185
Drug hypersensitivity 37.55 14.07 63 68815 80466 34807587
Peripheral swelling 37.45 14.07 58 68820 76483 34811570
Mood altered 37.43 14.07 65 68813 8887 34879166
Bronchitis 37.27 14.07 18 68860 41945 34846108
Decreased appetite 37.14 14.07 185 68693 166207 34721846
Delirium 36.82 14.07 178 68700 43813 34844240
Reversible cerebral vasoconstriction syndrome 36.82 14.07 18 68860 439 34887614
Haematoma 36.33 14.07 4 68874 25601 34862452
Heat stroke 36.24 14.07 23 68855 942 34887111
Pleurothotonus 36.23 14.07 25 68853 1180 34886873
Feeling guilty 36.23 14.07 16 68862 307 34887746
Psychosexual disorder 36.17 14.07 12 68866 100 34887953
Postictal psychosis 36.04 14.07 14 68864 191 34887862
Haemoptysis 36.01 14.07 12 68866 34994 34853059
Type 2 diabetes mellitus 35.84 14.07 90 68788 15942 34872111
Sopor 35.81 14.07 76 68802 12060 34875993
Withdrawal syndrome 35.61 14.07 77 68801 12378 34875675
Premature baby 35.61 14.07 102 68776 19531 34868522
Haemorrhage 34.77 14.07 30 68848 51340 34836713
Blood cholesterol increased 34.65 14.07 104 68774 20439 34867614
Fall 34.49 14.07 246 68632 202639 34685414
Blood creatinine increased 34.35 14.07 86 68792 94890 34793163
Cerebral haemorrhage 34.19 14.07 13 68865 34924 34853129
Juvenile idiopathic arthritis 34.16 14.07 29 68849 1868 34886185
Coma 34.13 14.07 179 68699 45499 34842554
Galactorrhoea 34.10 14.07 17 68861 433 34887620
Dopamine dysregulation syndrome 33.89 14.07 17 68861 439 34887614
Hallucination, visual 33.80 14.07 94 68784 17697 34870356
Somatic hallucination 33.50 14.07 9 68869 32 34888021
Drug abuse 33.45 14.07 320 68558 98776 34789277
Inappropriate schedule of product administration 32.96 14.07 223 68655 62073 34825980
Metabolic syndrome 32.72 14.07 27 68851 1672 34886381
Enuresis 32.54 14.07 31 68847 2322 34885731
Hyperphagia 32.51 14.07 25 68853 1398 34886655
Nasopharyngitis 32.37 14.07 55 68823 69913 34818140
Headache 32.32 14.07 247 68631 200388 34687665
Musculoskeletal stiffness 32.22 14.07 179 68699 46501 34841552
Rhinalgia 32.02 14.07 22 68856 1031 34887022
Hiccups 31.93 14.07 65 68813 10017 34878036
Posture abnormal 31.93 14.07 30 68848 2209 34885844
Foetal disorder 31.80 14.07 20 68858 806 34887247
Arthritis 31.80 14.07 11 68867 31335 34856718
Staring 31.79 14.07 25 68853 1445 34886608
Schizophreniform disorder 31.66 14.07 10 68868 70 34887983
Basilar artery occlusion 31.54 14.07 10 68868 71 34887982
Depressed level of consciousness 31.40 14.07 167 68711 42674 34845379
Sleep-related eating disorder 31.22 14.07 14 68864 279 34887774
Dysphoria 31.22 14.07 30 68848 2272 34885781
Chest discomfort 31.04 14.07 37 68841 54493 34833560
Maternal exposure during breast feeding 30.75 14.07 25 68853 1516 34886537
Cerebrovascular accident 30.51 14.07 77 68801 84734 34803319
Drug dependence 30.46 14.07 111 68767 24106 34863947
Insurance issue 30.38 14.07 28 68850 2011 34886042
Physical assault 30.36 14.07 22 68856 1123 34886930
Patient restraint 29.97 14.07 10 68868 85 34887968
Social problem 29.75 14.07 20 68858 904 34887149
Libido decreased 29.29 14.07 41 68837 4655 34883398
Depressive symptom 29.22 14.07 32 68846 2827 34885226
Rectal haemorrhage 29.12 14.07 22 68856 40227 34847826
Hallucinations, mixed 29.07 14.07 31 68847 2658 34885395
Soliloquy 29.06 14.07 15 68863 412 34887641
Toxicity to various agents 29.02 14.07 555 68323 199807 34688246
Hypokinesia 29.02 14.07 58 68820 8822 34879231
Imprisonment 28.97 14.07 16 68862 505 34887548
Antipsychotic drug level above therapeutic 28.91 14.07 22 68856 1211 34886842
Foetal distress syndrome 28.86 14.07 21 68857 1079 34886974
Delusional disorder, unspecified type 28.81 14.07 18 68860 717 34887336
Movement disorder 28.69 14.07 70 68808 12178 34875875
Troponin T increased 28.62 14.07 29 68849 2342 34885711
Blunted affect 28.47 14.07 14 68864 346 34887707
Dry skin 28.43 14.07 13 68865 31274 34856779
Product substitution issue 28.39 14.07 62 68816 10033 34878020
Stereotypy 28.30 14.07 18 68860 740 34887313
Male sexual dysfunction 28.11 14.07 13 68865 279 34887774
Ventricular septal defect 28.10 14.07 37 68841 3964 34884089
Compulsive hoarding 28.03 14.07 7 68871 17 34888036
Electrocardiogram QRS complex prolonged 27.99 14.07 41 68837 4853 34883200
Hyperreflexia 27.88 14.07 33 68845 3173 34884880
Restless legs syndrome 27.82 14.07 55 68823 8299 34879754
Hyperkinesia 27.76 14.07 25 68853 1743 34886310
Staphylococcal infection 27.68 14.07 15 68863 32745 34855308
Autism spectrum disorder 27.57 14.07 28 68850 2268 34885785
Skin lesion 27.49 14.07 5 68873 21956 34866097
Pulmonary valve incompetence 27.48 14.07 19 68859 900 34887153
Myelodysplastic syndrome 27.25 14.07 3 68875 19205 34868848
Eye movement disorder 27.20 14.07 37 68841 4090 34883963
Sudden cardiac death 27.20 14.07 35 68843 3666 34884387
Polydipsia 27.18 14.07 36 68842 3879 34884174
Rash maculo-papular 27.16 14.07 11 68867 28440 34859613
Poor quality sleep 27.07 14.07 54 68824 8202 34879851
Hypometabolism 27.05 14.07 10 68868 118 34887935
Antisocial behaviour 26.84 14.07 14 68864 393 34887660
Neutropenia neonatal 26.81 14.07 17 68861 695 34887358
Muscle contractions involuntary 26.72 14.07 25 68853 1831 34886222
High-grade B-cell lymphoma 26.54 14.07 10 68868 125 34887928
Cholestasis 26.42 14.07 10 68868 26938 34861115
Feeling abnormal 26.41 14.07 214 68664 63021 34825032
Erectile dysfunction 26.30 14.07 95 68783 20542 34867511
Coordination abnormal 26.28 14.07 51 68827 7593 34880460
No adverse event 26.27 14.07 102 68776 22825 34865228
Respiratory depression 26.23 14.07 81 68797 16164 34871889
Red cell distribution width decreased 26.23 14.07 11 68867 185 34887868
Herpes zoster 25.93 14.07 18 68860 34381 34853672
Obsessive thoughts 25.90 14.07 17 68861 738 34887315
Influenza 25.89 14.07 36 68842 49630 34838423
Accommodation disorder 25.88 14.07 12 68866 259 34887794
Skin ulcer 25.86 14.07 6 68872 22210 34865843
Blood thyroid stimulating hormone decreased 25.76 14.07 25 68853 1916 34886137
Abdominal pain upper 25.63 14.07 65 68813 71425 34816628
Blood glucose increased 25.32 14.07 221 68657 66497 34821556
Upper respiratory tract infection 25.32 14.07 17 68861 33042 34855011
Granulocytopenia 25.29 14.07 46 68832 6521 34881532
Diabetic coma 25.19 14.07 18 68860 899 34887154
Suicidal behaviour 25.16 14.07 22 68856 1475 34886578
Mood swings 25.09 14.07 51 68827 7850 34880203
Oedema 25.02 14.07 32 68846 45709 34842344
Pneumothorax 24.66 14.07 4 68874 19088 34868965
Pyramidal tract syndrome 24.54 14.07 11 68867 219 34887834
Dehydration 24.36 14.07 153 68725 129816 34758237
Upper gastrointestinal haemorrhage 24.14 14.07 10 68868 25508 34862545
Diverticulitis 24.10 14.07 5 68873 19999 34868054
Dysgeusia 24.09 14.07 11 68867 26486 34861567
Hypokalaemia 24.06 14.07 49 68829 58165 34829888
Poor personal hygiene 23.99 14.07 12 68866 308 34887745
Pneumonia aspiration 23.98 14.07 153 68725 41750 34846303
Thrombosis 23.95 14.07 39 68839 50419 34837634
Stupor 23.90 14.07 29 68849 2862 34885191
Device related infection 23.69 14.07 3 68875 17234 34870819
Impulse-control disorder 23.65 14.07 20 68858 1281 34886772
Ejaculation disorder 23.65 14.07 18 68860 991 34887062
Cataract 23.61 14.07 11 68867 26175 34861878
Inability to afford medication 23.50 14.07 21 68857 1449 34886604
Child abuse 23.43 14.07 13 68865 414 34887639
Tension 23.38 14.07 25 68853 2150 34885903
Blood pressure systolic increased 23.38 14.07 8 68870 22944 34865109
Homeless 23.36 14.07 6 68872 17 34888036
Adverse event 23.30 14.07 86 68792 18791 34869262
Arthropathy 23.20 14.07 12 68866 26895 34861158
Negative thoughts 23.17 14.07 15 68863 636 34887417
Altered state of consciousness 23.17 14.07 98 68780 22795 34865258
Iatrogenic injury 23.02 14.07 17 68861 894 34887159
Lymphocyte count abnormal 22.99 14.07 19 68859 1179 34886874
Slow speech 22.93 14.07 19 68859 1183 34886870
Anaphylactic reaction 22.93 14.07 18 68860 32283 34855770
Parkinsonian rest tremor 22.90 14.07 9 68869 127 34887926
Chest pain 22.85 14.07 151 68727 126611 34761442
Gaze palsy 22.63 14.07 22 68856 1690 34886363
Non-high-density lipoprotein cholesterol increased 22.52 14.07 9 68869 133 34887920
Reduced facial expression 22.40 14.07 18 68860 1073 34886980
Muscle contracture 22.36 14.07 19 68859 1225 34886828
Substance use 22.30 14.07 15 68863 679 34887374
Productive cough 22.22 14.07 25 68853 37788 34850265
Orthostatic hypertension 22.21 14.07 11 68867 276 34887777
Dysphemia 22.03 14.07 21 68857 1574 34886479
Bladder cancer 21.97 14.07 3 68875 16275 34871778
Platelet count decreased 21.88 14.07 142 68736 119575 34768478
Fluid retention 21.73 14.07 13 68865 26874 34861179
Nervousness 21.43 14.07 64 68814 12542 34875511
Foetal growth restriction 21.42 14.07 33 68845 4084 34883969
Incorrect dose administered 21.40 14.07 145 68733 40370 34847683
Haemorrhage intracranial 21.38 14.07 3 68875 15943 34872110
Cardiogenic shock 21.33 14.07 13 68865 26605 34861448
Sexually inappropriate behaviour 21.24 14.07 13 68865 499 34887554
Symptom recurrence 21.19 14.07 15 68863 738 34887315
Jaundice neonatal 21.07 14.07 19 68859 1327 34886726
Subdural haematoma 21.00 14.07 7 68871 20414 34867639
COVID-19 pneumonia 20.95 14.07 4 68874 16963 34871090
Gout 20.88 14.07 6 68872 19247 34868806
Full blood count decreased 20.83 14.07 5 68873 18083 34869970
Excessive masturbation 20.74 14.07 8 68870 107 34887946
Emotional distress 20.72 14.07 71 68807 14955 34873098
Coma scale abnormal 20.68 14.07 32 68846 3976 34884077
Weight decreased 20.63 14.07 235 68643 176066 34711987
Renal hypertension 20.61 14.07 9 68869 168 34887885
Flatulence 20.56 14.07 8 68870 21190 34866863
Suspiciousness 20.48 14.07 11 68867 328 34887725
Diabetic ketoacidosis 20.48 14.07 80 68798 17952 34870101
COVID-19 20.43 14.07 81 68797 77469 34810584
Chronic obstructive pulmonary disease 20.36 14.07 41 68837 48877 34839176
Eosinophilic myocarditis 20.34 14.07 13 68865 539 34887514
Gastrooesophageal reflux disease 20.26 14.07 27 68851 37897 34850156
Rebound psychosis 20.22 14.07 9 68869 176 34887877
Mucosal inflammation 20.12 14.07 28 68850 38594 34849459
Hypoglycaemia 20.12 14.07 49 68829 54591 34833462
Constipation 20.03 14.07 173 68705 136809 34751244
Swelling 19.87 14.07 33 68845 42333 34845720
Urinary retention 19.85 14.07 131 68747 36157 34851896
Hypoacusis 19.79 14.07 4 68874 16297 34871756
Bone pain 19.74 14.07 8 68870 20678 34867375
Energy increased 19.66 14.07 18 68860 1282 34886771
Sinus arrhythmia 19.66 14.07 15 68863 829 34887224
Anamnestic reaction 19.65 14.07 6 68872 37 34888016
Hunger 19.55 14.07 20 68858 1634 34886419
Negative symptoms in schizophrenia 19.51 14.07 6 68872 38 34888015
Gangrene neonatal 19.51 14.07 9 68869 192 34887861
Ejaculation delayed 19.46 14.07 10 68868 272 34887781
Diarrhoea infectious 19.41 14.07 13 68865 584 34887469
Muscular weakness 19.29 14.07 76 68802 72821 34815232
Nephrectasia 19.26 14.07 5 68873 15 34888038
Type 1 diabetes mellitus 19.23 14.07 32 68846 4226 34883827
Blood ketone body 19.14 14.07 7 68871 80 34887973
Rash pruritic 19.14 14.07 15 68863 26926 34861127
Haematemesis 18.97 14.07 16 68862 27695 34860358
Mutism 18.88 14.07 15 68863 880 34887173
Intentional product misuse 18.84 14.07 154 68724 45457 34842596
Hyperhidrosis 18.82 14.07 230 68648 75462 34812591
Drug withdrawal syndrome neonatal 18.82 14.07 29 68849 3590 34884463
Clostridium difficile colitis 18.81 14.07 4 68874 15726 34872327
Rhesus incompatibility 18.75 14.07 6 68872 44 34888009
Renal tubular necrosis 18.72 14.07 4 68874 15676 34872377
Gender dysphoria 18.64 14.07 6 68872 45 34888008
Autonomic nervous system imbalance 18.55 14.07 24 68854 2527 34885526
Candida infection 18.35 14.07 6 68872 17709 34870344
Emotional disorder 18.28 14.07 37 68841 5679 34882374
Bacteraemia 18.22 14.07 8 68870 19709 34868344
Tachyphrenia 18.09 14.07 17 68861 1252 34886801
Dysphagia 17.95 14.07 195 68683 62186 34825867
Weight decrease neonatal 17.73 14.07 10 68868 329 34887724
Accidental exposure to product by child 17.72 14.07 18 68860 1458 34886595
Troponin increased 17.66 14.07 56 68822 11333 34876720
Benign ethnic neutropenia 17.58 14.07 6 68872 55 34887998
Osteomyelitis 17.55 14.07 5 68873 16131 34871922
Delusional perception 17.50 14.07 8 68870 167 34887886
Dermatillomania 17.49 14.07 6 68872 56 34887997
Cloacal exstrophy 17.39 14.07 6 68872 57 34887996
Oligospermia 17.30 14.07 7 68871 107 34887946
Theft 17.24 14.07 9 68869 253 34887800
Fungal infection 17.22 14.07 5 68873 15930 34872123
Flat affect 17.20 14.07 14 68864 850 34887203
Angina pectoris 17.09 14.07 22 68856 31341 34856712
Encephalopathy 17.04 14.07 27 68851 35292 34852761
Ataxia 17.00 14.07 63 68815 13790 34874263
Neuroleptic-induced deficit syndrome 16.93 14.07 5 68873 27 34888026
Myalgia 16.81 14.07 97 68781 84013 34804040
Product reconstitution quality issue 16.79 14.07 7 68871 116 34887937
Toxic epidermal necrolysis 16.75 14.07 11 68867 21635 34866418
Hypertonia 16.68 14.07 30 68848 4216 34883837
Underweight 16.65 14.07 11 68867 483 34887570
Suicide threat 16.63 14.07 5 68873 29 34888024
Neoplasm progression 16.52 14.07 13 68865 23287 34864766
Poisoning deliberate 16.46 14.07 43 68835 7801 34880252
Rash erythematous 16.40 14.07 15 68863 24962 34863091
Flushing 16.40 14.07 24 68854 32396 34855657
Oxygen saturation decreased 16.30 14.07 53 68825 53765 34834288
Cardiomyopathy 16.27 14.07 71 68807 16737 34871316
Nasal discomfort 16.26 14.07 18 68860 1610 34886443
Impaired healing 16.22 14.07 5 68873 15329 34872724
Selective mutism 16.22 14.07 6 68872 71 34887982
Anticholinergic syndrome 16.20 14.07 16 68862 1253 34886800
Pulmonary fibrosis 16.17 14.07 8 68870 18388 34869665
Ventricular fibrillation 16.03 14.07 13 68865 22941 34865112
Diabetes insipidus 15.98 14.07 24 68854 2904 34885149
Divorced 15.94 14.07 4 68874 10 34888043
Generalised anxiety disorder 15.84 14.07 13 68865 799 34887254
Nephrolithiasis 15.79 14.07 22 68856 30311 34857742
Psoriasis 15.75 14.07 33 68845 38779 34849274
Hypospadias 15.74 14.07 25 68853 3176 34884877
Excessive sexual fantasies 15.70 14.07 3 68875 0 34888053
Complicated fracture 15.70 14.07 3 68875 0 34888053
Vomiting 15.66 14.07 370 68508 247251 34640802
Floppy iris syndrome 15.64 14.07 9 68869 308 34887745
Wolff-Parkinson-White syndrome 15.55 14.07 8 68870 218 34887835
Neutropenic sepsis 15.47 14.07 4 68874 13763 34874290
Transient ischaemic attack 15.43 14.07 19 68859 27594 34860459
Spasmodic dysphonia 15.42 14.07 8 68870 222 34887831
Lung disorder 15.38 14.07 28 68850 34668 34853385
Grandiosity 15.35 14.07 9 68869 319 34887734
Inappropriate affect 15.30 14.07 12 68866 691 34887362
Compulsions 15.04 14.07 8 68870 234 34887819
Logorrhoea 14.86 14.07 21 68857 2405 34885648
High density lipoprotein decreased 14.84 14.07 25 68853 3335 34884718
Abdominal discomfort 14.82 14.07 64 68814 59771 34828282
Social anxiety disorder 14.81 14.07 9 68869 341 34887712
Behaviour disorder 14.78 14.07 31 68847 4879 34883174
Prader-Willi syndrome 14.72 14.07 4 68874 15 34888038
Lung neoplasm malignant 14.64 14.07 8 68870 17387 34870666
Eosinophil count decreased 14.62 14.07 16 68862 1412 34886641
Acute respiratory failure 14.59 14.07 24 68854 30904 34857149
Mobility decreased 14.57 14.07 23 68855 30105 34857948
Blood pressure fluctuation 14.50 14.07 17 68861 25232 34862821
Hypomagnesaemia 14.49 14.07 13 68865 21838 34866215
Pulmonary hypertension 14.42 14.07 12 68866 20912 34867141
Hypocalcaemia 14.34 14.07 16 68862 24273 34863780
Hypernatraemia 14.33 14.07 43 68835 8447 34879606
Skin turgor decreased 14.33 14.07 10 68868 481 34887572
Hip fracture 14.33 14.07 3 68875 11922 34876131
Condition aggravated 14.28 14.07 487 68391 191709 34696344
Neoplasm malignant 14.24 14.07 11 68867 19894 34868159
Dizziness 14.23 14.07 325 68553 218196 34669857
Ketosis 14.20 14.07 10 68868 488 34887565
Angioedema 14.16 14.07 33 68845 37341 34850712
Adrenal insufficiency 14.13 14.07 5 68873 14042 34874011
Moaning 14.12 14.07 12 68866 774 34887279
Bipolar I disorder 14.11 14.07 12 68866 775 34887278
Impaired self-care 14.09 14.07 15 68863 1283 34886770

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 2162.96 11.83 817 131095 12442 79600034
Dystonia 1883.35 11.83 848 131064 20551 79591925
Tardive dyskinesia 1865.14 11.83 690 131222 9881 79602595
Extrapyramidal disorder 1789.46 11.83 833 131079 21846 79590630
Neuroleptic malignant syndrome 1673.09 11.83 846 131066 26713 79585763
Sedation 1504.98 11.83 984 130928 50911 79561565
Suicide attempt 1442.61 11.83 1153 130759 81779 79530697
Psychotic disorder 1402.16 11.83 866 131046 40536 79571940
Dyskinesia 1320.23 11.83 858 131054 43915 79568561
Parkinsonism 1209.18 11.83 577 131335 16007 79596469
Sexual dysfunction 1174.71 11.83 453 131459 7310 79605166
Delusion 1129.58 11.83 589 131323 19834 79592642
Blood prolactin abnormal 1090.26 11.83 352 131560 3249 79609227
Product use in unapproved indication 1068.95 11.83 1663 130249 248696 79363780
Hallucination, auditory 1040.39 11.83 560 131352 20133 79592343
Suicidal ideation 1011.85 11.83 908 131004 75432 79537044
Weight increased 839.74 11.83 1582 130330 275804 79336672
Anosognosia 826.61 11.83 289 131623 3475 79609001
Disturbance in social behaviour 737.60 11.83 286 131626 4684 79607792
Mania 708.43 11.83 417 131495 17843 79594633
Treatment noncompliance 679.11 11.83 615 131297 51653 79560823
Hyperprolactinaemia 654.83 11.83 258 131654 4418 79608058
Metabolic disorder 649.94 11.83 313 131599 8857 79603619
Aggression 637.45 11.83 587 131325 50371 79562105
Agitation 609.19 11.83 787 131125 98928 79513548
Tremor 559.13 11.83 1006 130906 169077 79443399
Schizophrenia 550.57 11.83 334 131578 15106 79597370
Restlessness 541.95 11.83 515 131397 45977 79566499
Gambling disorder 524.62 11.83 176 131736 1850 79610626
Abnormal behaviour 521.73 11.83 453 131459 35968 79576508
Personality change 518.84 11.83 278 131634 9892 79602584
Drug interaction 508.85 11.83 1675 130237 413508 79198968
Salivary hypersecretion 507.97 11.83 308 131604 13916 79598560
Oculogyric crisis 503.33 11.83 188 131724 2764 79609712
Intentional self-injury 463.89 11.83 403 131509 32016 79580460
Psychotic symptom 449.79 11.83 169 131743 2528 79609948
Muscle rigidity 429.92 11.83 315 131597 19567 79592909
Intentional overdose 411.36 11.83 675 131237 105285 79507191
Anxiety 391.63 11.83 1096 130816 247416 79365060
Irritability 375.14 11.83 399 131513 40745 79571731
Somnolence 366.77 11.83 1044 130868 237937 79374539
Blood creatine phosphokinase increased 362.46 11.83 495 131417 65595 79546881
Dyspnoea 343.16 11.83 557 131355 856468 78756008
Arthralgia 339.12 11.83 270 131642 571533 79040943
Catatonia 334.43 11.83 198 131714 8558 79603918
Thinking abnormal 334.16 11.83 230 131682 12931 79599545
Diarrhoea 326.29 11.83 601 131311 879888 78732588
Psychomotor hyperactivity 313.42 11.83 244 131668 16605 79595871
Joint swelling 313.09 11.83 51 131861 288595 79323881
Stubbornness 305.28 11.83 80 131832 315 79612161
Electrocardiogram QT prolonged 302.26 11.83 539 131373 89847 79522629
Febrile neutropenia 286.72 11.83 26 131886 230973 79381503
Psychiatric symptom 284.26 11.83 165 131747 6870 79605606
Hypersexuality 282.80 11.83 106 131806 1574 79610902
Pain 280.84 11.83 458 131454 703344 78909132
Psychiatric decompensation 279.99 11.83 135 131777 3828 79608648
Prescribed underdose 263.34 11.83 283 131629 29231 79583245
Infusion related reaction 262.76 11.83 35 131877 230202 79382274
Anaemia 256.32 11.83 216 131696 444799 79167677
Persecutory delusion 255.47 11.83 136 131776 4773 79607703
Galactorrhoea 244.95 11.83 120 131792 3526 79608950
Pneumonia 242.08 11.83 453 131459 659793 78952683
Mental impairment 239.30 11.83 220 131692 18816 79593660
Blood glucose increased 233.30 11.83 558 131354 114417 79498059
Social avoidant behaviour 229.96 11.83 126 131786 4688 79607788
Overdose 228.29 11.83 747 131165 183459 79429017
Serotonin syndrome 224.12 11.83 322 131590 44705 79567771
Orthostatic hypertension 221.14 11.83 74 131838 771 79611705
Blood prolactin increased 216.88 11.83 114 131798 3897 79608579
Underdose 213.81 11.83 269 131643 32882 79579594
Drug abuse 212.68 11.83 672 131240 162019 79450457
Paranoia 212.66 11.83 208 131704 19224 79593252
Metabolic syndrome 210.87 11.83 99 131813 2641 79609835
Emotional poverty 205.92 11.83 71 131841 816 79611660
Arthropathy 199.50 11.83 28 131884 177083 79435393
Obesity 196.93 11.83 266 131646 34859 79577617
Hallucination 196.90 11.83 437 131475 85308 79527168
Apathy 193.06 11.83 165 131747 12812 79599664
Obsessive-compulsive disorder 192.92 11.83 121 131791 5806 79606670
Drooling 190.28 11.83 120 131792 5814 79606662
Cough 189.90 11.83 196 131716 366593 79245883
Synovitis 186.89 11.83 17 131895 150717 79461759
Rheumatoid arthritis 185.56 11.83 57 131855 208413 79404063
Cogwheel rigidity 182.00 11.83 93 131819 2995 79609481
Swelling 181.12 11.83 66 131846 216645 79395831
Antipsychotic drug level increased 172.56 11.83 113 131799 5844 79606632
Mental disorder 172.37 11.83 235 131677 31067 79581409
Gestational diabetes 171.70 11.83 115 131797 6178 79606298
Mood altered 167.82 11.83 176 131736 17671 79594805
Malignant neoplasm progression 166.83 11.83 16 131896 135974 79476502
Rash 162.28 11.83 458 131454 577900 79034576
Hypomania 159.62 11.83 118 131794 7426 79605050
Depression 159.62 11.83 746 131166 216044 79396432
Priapism 159.41 11.83 97 131815 4408 79608068
Sinusitis 159.25 11.83 62 131850 195439 79417037
Diabetes mellitus 157.40 11.83 379 131533 78011 79534465
Compulsive shopping 153.98 11.83 56 131856 760 79611716
Tic 150.54 11.83 81 131831 2905 79609571
Affective disorder 149.37 11.83 118 131794 8201 79604275
Systemic lupus erythematosus 149.28 11.83 14 131898 121135 79491341
Prescribed overdose 147.76 11.83 242 131670 37641 79574835
Homicidal ideation 147.46 11.83 84 131828 3373 79609103
Abdominal discomfort 146.26 11.83 120 131792 250607 79361869
Contraindicated product administered 145.82 11.83 40 131872 157498 79454978
Schizoaffective disorder 145.08 11.83 71 131841 2081 79610395
Disinhibition 143.77 11.83 75 131837 2523 79609953
Pruritus 142.36 11.83 273 131639 394375 79218101
Drug monitoring procedure incorrectly performed 141.25 11.83 46 131866 437 79612039
Bruxism 140.69 11.83 86 131826 3940 79608536
Increased appetite 140.09 11.83 133 131779 11845 79600631
Hypothermia 139.45 11.83 180 131732 22566 79589910
Drug ineffective 139.03 11.83 2532 129380 1078381 78534095
Acute kidney injury 138.60 11.83 421 131491 518983 79093493
Insomnia 137.55 11.83 782 131130 244388 79368088
Hypersensitivity 135.79 11.83 140 131772 262099 79350377
Sopor 135.74 11.83 216 131696 32794 79579682
Maternal exposure during pregnancy 134.84 11.83 514 131398 136024 79476452
Rhabdomyolysis 134.69 11.83 426 131486 102705 79509771
Posture abnormal 133.61 11.83 82 131830 3784 79608692
Drug hypersensitivity 130.93 11.83 182 131730 298734 79313742
Disease progression 130.69 11.83 71 131841 184291 79428185
Impulse-control disorder 130.08 11.83 62 131850 1712 79610764
Nasopharyngitis 129.80 11.83 137 131775 253744 79358732
Infection 126.32 11.83 128 131784 241584 79370892
General physical health deterioration 126.22 11.83 162 131750 275076 79337400
Hostility 125.88 11.83 66 131846 2244 79610232
Drug intolerance 125.79 11.83 151 131761 263968 79348508
Glossodynia 124.54 11.83 13 131899 103324 79509152
Pain in extremity 123.89 11.83 261 131651 364277 79248199
Stomatitis 123.77 11.83 44 131868 146713 79465763
Fatigue 123.50 11.83 967 130945 928760 78683716
Back pain 121.80 11.83 197 131715 303983 79308493
Off label use 121.70 11.83 2140 129772 905075 78707401
Product administered to patient of inappropriate age 120.06 11.83 88 131824 5465 79607011
Suppressed lactation 119.89 11.83 37 131875 290 79612186
Sepsis 119.03 11.83 163 131749 269265 79343211
Completed suicide 117.51 11.83 752 131160 245015 79367461
Euphoric mood 116.48 11.83 99 131813 7627 79604849
Insurance issue 115.33 11.83 87 131825 5646 79606830
Compulsive sexual behaviour 114.76 11.83 34 131878 228 79612248
Depressed mood 114.56 11.83 250 131662 48230 79564246
Seizure 113.67 11.83 614 131298 188220 79424256
Peripheral swelling 113.29 11.83 169 131743 269448 79343028
Dysarthria 111.93 11.83 304 131608 67318 79545158
Impulsive behaviour 111.84 11.83 66 131846 2834 79609642
Sinus tachycardia 111.80 11.83 211 131701 36697 79575779
Logorrhoea 107.78 11.83 75 131837 4290 79608186
Muscle twitching 107.31 11.83 166 131746 24598 79587878
Pyrexia 106.07 11.83 673 131239 678036 78934440
Urinary incontinence 105.95 11.83 219 131693 40690 79571786
Libido increased 105.71 11.83 56 131856 1945 79610531
Abdominal pain 105.08 11.83 314 131598 389255 79223221
Torticollis 104.51 11.83 59 131853 2328 79610148
Urticaria 102.66 11.83 93 131819 185108 79427368
Antipsychotic drug level below therapeutic 102.32 11.83 47 131865 1191 79611285
Delusion of grandeur 101.82 11.83 49 131863 1383 79611093
Myocarditis 101.71 11.83 151 131761 21582 79590894
Bradykinesia 99.23 11.83 92 131820 7951 79604525
Economic problem 99.09 11.83 56 131856 2214 79610262
Bradyphrenia 98.38 11.83 104 131808 10536 79601940
Impaired healing 98.34 11.83 14 131898 87641 79524835
Thrombocytopenia 97.76 11.83 181 131731 265078 79347398
Affect lability 96.98 11.83 106 131806 11153 79601323
Trismus 96.98 11.83 77 131835 5390 79607086
Gastrointestinal haemorrhage 96.08 11.83 63 131849 147656 79464820
Arthritis 95.91 11.83 35 131877 114845 79497631
Infarction 95.44 11.83 71 131841 4511 79607965
Nausea 95.05 11.83 1070 130842 956126 78656350
Pleural effusion 94.42 11.83 62 131850 145200 79467276
Asthenia 94.10 11.83 481 131431 511208 79101268
Hyperphagia 93.00 11.83 56 131856 2496 79609980
Paradoxical drug reaction 92.17 11.83 84 131828 7101 79605375
Gaze palsy 91.95 11.83 59 131853 2946 79609530
Antipsychotic drug level decreased 90.43 11.83 43 131869 1181 79611295
Blood triglycerides increased 89.71 11.83 140 131772 20900 79591576
Oppositional defiant disorder 89.67 11.83 33 131879 464 79612012
Altered state of consciousness 89.15 11.83 213 131699 43609 79568867
Osteoarthritis 89.00 11.83 18 131894 87291 79525185
Cardiac failure congestive 88.27 11.83 64 131848 142338 79470138
Depressive symptom 88.14 11.83 78 131834 6345 79606131
Discomfort 88.10 11.83 49 131863 125568 79486908
Erythema 88.04 11.83 146 131766 223144 79389332
Disturbance in attention 87.72 11.83 232 131680 50569 79561907
Caesarean section 87.71 11.83 106 131806 12429 79600047
Stupor 87.49 11.83 80 131832 6792 79605684
Ascites 87.31 11.83 11 131901 75551 79536925
Amenorrhoea 87.28 11.83 84 131828 7608 79604868
Atrial fibrillation 87.08 11.83 120 131792 197766 79414710
Lower respiratory tract infection 86.94 11.83 53 131859 129167 79483309
Musculoskeletal pain 85.76 11.83 31 131881 102323 79510153
Bipolar disorder 85.26 11.83 83 131829 7624 79604852
Coma 85.03 11.83 361 131551 100288 79512188
Rabbit syndrome 84.05 11.83 29 131883 334 79612142
Speech disorder 83.43 11.83 238 131674 54207 79558269
Personality disorder 83.07 11.83 74 131838 6072 79606404
Gambling 81.40 11.83 27 131885 273 79612203
Mobility decreased 80.96 11.83 51 131861 122124 79490352
Therapeutic product effect decreased 80.86 11.83 91 131821 163772 79448704
Alopecia 79.91 11.83 164 131748 231191 79381285
Urinary retention 79.55 11.83 240 131672 56390 79556086
Hallucination, visual 77.57 11.83 169 131743 32560 79579916
Self-injurious ideation 77.18 11.83 57 131855 3581 79608895
Tachycardia 75.90 11.83 529 131383 177239 79435237
Psychomotor retardation 74.87 11.83 70 131842 6114 79606362
Neuropathy peripheral 74.73 11.83 74 131838 141231 79471245
Choreoathetosis 74.73 11.83 41 131871 1529 79610947
Blood prolactin decreased 74.66 11.83 25 131887 261 79612215
Acute psychosis 74.42 11.83 59 131853 4121 79608355
Wheezing 74.19 11.83 51 131861 116613 79495863
Renal failure 74.14 11.83 137 131775 200831 79411645
Eosinophil count decreased 73.83 11.83 54 131858 3342 79609134
Mutism 73.64 11.83 47 131865 2325 79610151
Pleurothotonus 73.54 11.83 48 131864 2468 79610008
Sedation complication 73.51 11.83 109 131803 15560 79596916
Bipolar I disorder 73.18 11.83 45 131867 2084 79610392
Abortion spontaneous 72.95 11.83 155 131757 29352 79583124
Blister 72.36 11.83 55 131857 119421 79493055
Withdrawal syndrome 72.18 11.83 146 131766 26708 79585768
Folliculitis 72.10 11.83 5 131907 55375 79557101
Hallucinations, mixed 72.05 11.83 72 131840 6827 79605649
Wrong technique in product usage process 71.97 11.83 277 131635 73598 79538878
Dyslipidaemia 71.21 11.83 92 131820 11541 79600935
Sleep disorder 70.59 11.83 305 131607 85372 79527104
Anger 70.14 11.83 112 131800 17050 79595426
Melaena 70.02 11.83 9 131903 60881 79551595
Symptom recurrence 69.73 11.83 45 131867 2269 79610207
Hypertonia 69.21 11.83 72 131840 7160 79605316
Water intoxication 69.08 11.83 31 131881 743 79611733
Refusal of examination 68.80 11.83 22 131890 196 79612280
Hepatic enzyme increased 68.68 11.83 123 131789 182487 79429989
Herpes zoster 68.68 11.83 34 131878 93049 79519427
Mood swings 68.25 11.83 120 131792 19760 79592716
Blunted affect 68.10 11.83 27 131885 470 79612006
Hypokinesia 67.98 11.83 117 131795 18943 79593533
Abdominal pain upper 67.29 11.83 171 131741 223648 79388828
Colitis 67.09 11.83 19 131893 73288 79539188
Septic shock 66.45 11.83 63 131849 122738 79489738
Stereotypy 66.18 11.83 32 131880 913 79611563
Victim of child abuse 65.92 11.83 32 131880 921 79611555
Enuresis 65.67 11.83 49 131863 3127 79609349
Oromandibular dystonia 65.67 11.83 33 131879 1025 79611451
Substance abuse 65.62 11.83 84 131828 10442 79602034
Hospitalisation 65.41 11.83 319 131593 93917 79518559
Irritable bowel syndrome 65.20 11.83 12 131900 62229 79550247
Decreased appetite 65.08 11.83 318 131594 342100 79270376
Inappropriate affect 64.65 11.83 37 131875 1499 79610977
Muscle injury 64.35 11.83 4 131908 48557 79563919
Pregnancy on contraceptive 64.12 11.83 31 131881 884 79611592
Sudden death 63.64 11.83 125 131787 22386 79590090
Plasma cell myeloma 63.40 11.83 7 131905 53252 79559224
Neutrophil count increased 63.18 11.83 146 131766 29250 79583226
Multiple organ dysfunction syndrome 62.40 11.83 64 131848 120182 79492294
Gastrointestinal disorder 62.34 11.83 66 131846 122139 79490337
Skin ulcer 62.27 11.83 8 131904 54142 79558334
Normal newborn 61.64 11.83 67 131845 7005 79605471
Antipsychotic drug level above therapeutic 61.57 11.83 40 131872 2040 79610436
Intentional product use issue 61.30 11.83 98 131814 152014 79460462
Wound 61.25 11.83 61 131851 116118 79496358
Pancytopenia 61.11 11.83 113 131799 165632 79446844
Restless legs syndrome 61.01 11.83 115 131797 19977 79592499
Paraesthesia 60.86 11.83 125 131787 176198 79436278
Vertigo 60.06 11.83 250 131662 68832 79543644
Soliloquy 59.94 11.83 27 131885 653 79611823
Headache 59.62 11.83 744 131168 653028 78959448
Epistaxis 59.42 11.83 58 131854 111457 79501019
Upper respiratory tract infection 59.11 11.83 39 131873 91129 79521347
Haematochezia 58.88 11.83 36 131876 87609 79524867
Gynaecomastia 58.78 11.83 68 131844 7613 79604863
Suicidal behaviour 58.17 11.83 46 131866 3201 79609275
Dyspnoea exertional 58.16 11.83 36 131876 87037 79525439
Coronary artery disease 58.03 11.83 18 131894 65456 79547020
International normalised ratio increased 58.03 11.83 34 131878 84687 79527789
Refusal of treatment by patient 58.02 11.83 73 131839 8918 79603558
Dysphagia 57.85 11.83 373 131539 121763 79490713
Pneumonitis 57.14 11.83 15 131897 60845 79551631
Hypoxia 57.00 11.83 52 131860 103191 79509285
Dystonic tremor 56.60 11.83 19 131893 200 79612276
Electrocardiogram QRS complex prolonged 56.13 11.83 79 131833 10754 79601722
Haemoptysis 56.13 11.83 12 131900 55987 79556489
Death 56.12 11.83 633 131279 565881 79046595
Granulocytopenia 55.76 11.83 81 131831 11350 79601126
Parkinsonian rest tremor 55.70 11.83 20 131892 261 79612215
Eosinophilic myocarditis 55.66 11.83 31 131881 1191 79611285
Cytomegalovirus infection 55.08 11.83 4 131908 42640 79569836
Flat affect 54.97 11.83 37 131875 2004 79610472
Trimethylaminuria 54.63 11.83 18 131894 178 79612298
Depressed level of consciousness 54.57 11.83 309 131603 96343 79516133
Cerebral haemorrhage 54.56 11.83 14 131898 57659 79554817
Myelosuppression 54.37 11.83 3 131909 40293 79572183
Delirium 54.17 11.83 280 131632 84347 79528129
Interstitial lung disease 53.95 11.83 64 131848 112536 79499940
Hyperkalaemia 53.77 11.83 66 131846 114332 79498144
Decreased eye contact 53.75 11.83 27 131885 838 79611638
Accidental exposure to product by child 53.60 11.83 42 131870 2884 79609592
Mydriasis 53.59 11.83 101 131811 17542 79594934
Psychomotor skills impaired 53.49 11.83 54 131858 5183 79607293
Contusion 53.47 11.83 103 131809 148673 79463803
Delusional disorder, unspecified type 53.31 11.83 26 131886 756 79611720
Keratoconus 53.29 11.83 16 131896 113 79612363
Obsessive thoughts 52.34 11.83 29 131883 1103 79611373
Oedema peripheral 52.24 11.83 227 131685 252061 79360415
Hyperthermia 52.01 11.83 101 131811 17936 79594540
Ill-defined disorder 51.80 11.83 22 131890 65853 79546623
Rectal haemorrhage 51.73 11.83 31 131881 76269 79536207
Poisoning deliberate 51.36 11.83 103 131809 18725 79593751
Abortion induced 51.19 11.83 61 131851 7048 79605428
Product substitution issue 50.76 11.83 107 131805 20149 79592327
Osteonecrosis of jaw 50.65 11.83 6 131906 43220 79569256
Live birth 50.49 11.83 102 131810 18642 79593834
Pericarditis 50.20 11.83 59 131853 104177 79508299
Eye movement disorder 50.05 11.83 64 131848 7947 79604529
Bronchitis 50.01 11.83 87 131825 130557 79481919
Psoriatic arthropathy 49.72 11.83 34 131878 77965 79534511
Urinary tract infection 49.26 11.83 260 131652 274252 79338224
Anxiolytic therapy 49.25 11.83 13 131899 53 79612423
Drug therapy enhancement 49.25 11.83 13 131899 53 79612423
Bone marrow failure 49.13 11.83 12 131900 51095 79561381
Hallucination, olfactory 48.24 11.83 21 131891 467 79612009
Electrocardiogram QT shortened 48.19 11.83 17 131895 210 79612266
Productive cough 48.16 11.83 45 131867 88286 79524190
Pneumonia aspiration 48.13 11.83 229 131683 66738 79545738
Diverticulitis 47.80 11.83 9 131903 45927 79566549
Pregnancy 47.75 11.83 124 131788 26727 79585749
Haemoglobin decreased 47.74 11.83 197 131715 221922 79390554
Antidepressant drug level above therapeutic 47.67 11.83 23 131889 653 79611823
Hyperhidrosis 47.60 11.83 420 131492 151072 79461404
Epidural lipomatosis 47.49 11.83 28 131884 1200 79611276
Delusional disorder, persecutory type 47.43 11.83 21 131891 487 79611989
Vomiting 47.27 11.83 796 131116 665032 78947444
Accommodation disorder 47.23 11.83 22 131890 576 79611900
Blood pressure systolic increased 47.14 11.83 26 131886 66960 79545516
Behaviour disorder 46.83 11.83 55 131857 6258 79606218
Blepharospasm 46.81 11.83 53 131859 5798 79606678
Sleep-related eating disorder 46.47 11.83 23 131889 691 79611785
Abortion 46.43 11.83 29 131883 1381 79611095
Hypercalcaemia 45.87 11.83 5 131907 38425 79574051
Hepatotoxicity 45.72 11.83 14 131898 51338 79561138
Physical assault 45.30 11.83 30 131882 1581 79610895
Dysphoria 45.06 11.83 47 131865 4687 79607789
Akinesia 45.00 11.83 40 131872 3272 79609204
Analgesic drug level above therapeutic 44.97 11.83 20 131892 469 79612007
Reduced facial expression 44.93 11.83 37 131875 2728 79609748
Bankruptcy 44.78 11.83 11 131901 31 79612445
Cytokine release syndrome 44.76 11.83 4 131908 35994 79576482
Hyperreflexia 44.72 11.83 62 131850 8323 79604153
Acute myocardial infarction 44.71 11.83 37 131875 76999 79535477
Oedema 44.54 11.83 81 131831 119499 79492977
Homosexuality 44.52 11.83 11 131901 32 79612444
Binge eating 44.20 11.83 20 131892 489 79611987
Weight decreased 43.89 11.83 376 131536 354822 79257654
Red blood cell sedimentation rate increased 43.75 11.83 11 131901 45931 79566545
Fluid retention 43.74 11.83 31 131881 69778 79542698
Pulmonary fibrosis 43.11 11.83 10 131902 44102 79568374
Parkinsonian gait 43.05 11.83 24 131888 924 79611552
Mucosal inflammation 43.00 11.83 37 131875 75543 79536933
Sexually inappropriate behaviour 42.89 11.83 20 131892 525 79611951
Haematuria 42.56 11.83 31 131881 68805 79543671
Negative symptoms in schizophrenia 42.53 11.83 14 131898 138 79612338
Injection site erythema 42.44 11.83 40 131872 78157 79534319
Substance-induced psychotic disorder 42.26 11.83 39 131873 3350 79609126
Cardiac failure 42.25 11.83 124 131788 154718 79457758
Staring 42.16 11.83 35 131877 2610 79609866
Chest pain 41.87 11.83 284 131628 282020 79330456
Ataxia 41.85 11.83 113 131799 24926 79587550
Anaphylactic reaction 41.85 11.83 46 131866 83697 79528779
Basal cell carcinoma 41.84 11.83 6 131906 37369 79575107
Cognitive disorder 41.76 11.83 227 131685 69699 79542777
Psychotic behaviour 41.73 11.83 25 131887 1104 79611372
Crying 41.58 11.83 107 131805 22936 79589540
Generalised tonic-clonic seizure 41.42 11.83 163 131749 43747 79568729
Type 1 diabetes mellitus 41.23 11.83 54 131858 6865 79605611
Movement disorder 40.63 11.83 118 131794 27141 79585335
Tachyphrenia 40.59 11.83 31 131881 2049 79610427
Prostate cancer 40.56 11.83 4 131908 33264 79579212
Oropharyngeal spasm 40.47 11.83 18 131894 422 79612054
Floppy iris syndrome 40.44 11.83 17 131895 346 79612130
Hiccups 40.35 11.83 65 131847 9966 79602510
Tongue movement disturbance 40.32 11.83 18 131894 426 79612050
Threatened labour 40.31 11.83 20 131892 604 79611872
Personality change due to a general medical condition 39.76 11.83 15 131897 227 79612249
Dehydration 39.69 11.83 244 131668 247943 79364533
Somatic hallucination 39.69 11.83 11 131901 56 79612420
Malaise 39.67 11.83 571 131341 489298 79123178
Acute myeloid leukaemia 39.59 11.83 3 131909 30882 79581594
Myoclonus 39.57 11.83 118 131794 27542 79584934
Chest discomfort 39.54 11.83 108 131804 137936 79474540
Feeling guilty 39.48 11.83 22 131890 846 79611630
Somnambulism 39.41 11.83 48 131864 5673 79606803
Blood pressure fluctuation 39.27 11.83 32 131880 67113 79545363
Disturbance in sexual arousal 39.22 11.83 15 131897 236 79612240
Negative thoughts 39.21 11.83 26 131886 1373 79611103
Abulia 38.77 11.83 23 131889 997 79611479
Renal impairment 38.40 11.83 133 131779 157650 79454826
Inappropriate antidiuretic hormone secretion 38.35 11.83 113 131799 26200 79586276
Pulmonary valve incompetence 38.32 11.83 29 131883 1891 79610585
COVID-19 38.31 11.83 133 131779 157541 79454935
Palmar-plantar erythrodysaesthesia syndrome 37.85 11.83 5 131907 33129 79579347
Exhibitionism 37.84 11.83 10 131902 41 79612435
Abdominal distension 37.84 11.83 89 131823 119561 79492915
Chills 37.70 11.83 137 131775 160097 79452379
Schizophreniform disorder 37.42 11.83 13 131899 153 79612323
Bone pain 37.29 11.83 23 131889 55719 79556757
Libido decreased 37.23 11.83 45 131867 5276 79607200
Hyperkinesia 37.16 11.83 33 131879 2696 79609780
Autonomic nervous system imbalance 37.14 11.83 42 131870 4588 79607888
Injection site pruritus 36.80 11.83 12 131900 42271 79570205
Treatment failure 36.75 11.83 151 131761 170335 79442141
Osteoporosis 36.66 11.83 22 131890 54090 79558386
Knee arthroplasty 36.38 11.83 13 131899 43235 79569241
Myocardial infarction 36.10 11.83 169 131743 183960 79428516
Lactation disorder 35.94 11.83 14 131898 232 79612244
Toxicity to various agents 35.90 11.83 932 130980 420608 79191868
Joint range of motion decreased 35.76 11.83 6 131906 33276 79579200
Loss of libido 35.64 11.83 32 131880 2653 79609823
Morbid thoughts 35.59 11.83 20 131892 782 79611694
Divorced 35.51 11.83 9 131903 30 79612446
Polydipsia 35.47 11.83 49 131863 6556 79605920
Tension 35.41 11.83 40 131872 4364 79608112
Influenza 35.20 11.83 104 131808 129502 79482974
Muscle contractions involuntary 35.16 11.83 37 131875 3728 79608748
Paraphilia 35.14 11.83 10 131902 57 79612419
Neoplasm progression 35.03 11.83 21 131891 51661 79560815
Therapeutic product effect variable 35.00 11.83 28 131884 1981 79610495
Resting tremor 34.92 11.83 25 131887 1496 79610980
Platelet count decreased 34.55 11.83 185 131727 194479 79417997
Dry skin 34.36 11.83 37 131875 67958 79544518
Negativism 34.22 11.83 20 131892 843 79611633
Pulmonary mass 34.09 11.83 4 131908 29030 79583446
Diabetic ketoacidosis 34.09 11.83 129 131783 33993 79578483
Drug level increased 34.07 11.83 143 131769 39508 79572968
Reversible cerebral vasoconstriction syndrome 33.96 11.83 33 131879 3024 79609452
Suspiciousness 33.88 11.83 18 131894 629 79611847
Social problem 33.86 11.83 24 131888 1414 79611062
Bone marrow oedema syndrome 33.84 11.83 9 131903 38 79612438
Inappropriate schedule of product administration 33.82 11.83 354 131558 133274 79479202
Autism spectrum disorder 33.72 11.83 22 131890 1130 79611346
Tongue biting 33.67 11.83 28 131884 2093 79610383
Inflammation 33.59 11.83 65 131847 93688 79518788
Rebound effect 33.51 11.83 50 131862 7176 79605300
Cataract 33.44 11.83 32 131880 62088 79550388
Ideas of reference 33.32 11.83 12 131900 158 79612318
Alice in wonderland syndrome 33.29 11.83 9 131903 41 79612435
Epilepsy 33.29 11.83 145 131767 40715 79571761
Respiratory depression 33.21 11.83 111 131801 27519 79584957
Thrombosis 33.11 11.83 55 131857 84045 79528431
Metastases to liver 33.00 11.83 4 131908 28310 79584166
Erectile dysfunction 32.80 11.83 74 131838 14590 79597886
Head titubation 32.68 11.83 20 131892 918 79611558
Psychosexual disorder 32.58 11.83 11 131901 118 79612358
Fibromyalgia 32.53 11.83 35 131877 64305 79548171
Diabetic coma 32.07 11.83 22 131890 1229 79611247
Vision blurred 31.92 11.83 291 131621 105607 79506869
Troponin T increased 31.81 11.83 34 131878 3488 79608988
Muscle contracture 31.52 11.83 28 131884 2289 79610187
Nephrogenic diabetes insipidus 31.46 11.83 27 131885 2107 79610369
Drug effective for unapproved indication 31.45 11.83 44 131868 5957 79606519
Myelodysplastic syndrome 31.39 11.83 6 131906 30295 79582181
Hip arthroplasty 31.38 11.83 10 131902 35746 79576730
Oxygen saturation decreased 31.25 11.83 109 131803 128938 79483538
Postural tremor 31.12 11.83 18 131894 744 79611732
Neutropenic sepsis 31.11 11.83 4 131908 27060 79585416
Slow response to stimuli 30.87 11.83 25 131887 1800 79610676
Patient restraint 30.71 11.83 10 131902 95 79612381
Gastric ulcer 30.63 11.83 9 131903 33896 79578580
Conversion disorder 30.44 11.83 25 131887 1836 79610640
Suicide threat 30.42 11.83 9 131903 60 79612416
Miosis 30.24 11.83 75 131837 15714 79596762
Electroencephalogram abnormal 30.21 11.83 41 131871 5393 79607083
Chronic kidney disease 30.21 11.83 39 131873 66115 79546361
Rash pruritic 29.94 11.83 45 131867 71584 79540892
Birdshot chorioretinopathy 29.92 11.83 9 131903 64 79612412
Hypoprolactinaemia 29.85 11.83 7 131905 15 79612461
Grandiosity 29.80 11.83 16 131896 571 79611905
Bursitis 29.77 11.83 11 131901 35833 79576643
Nuchal rigidity 29.70 11.83 20 131892 1084 79611392
Drug screen false positive 29.62 11.83 20 131892 1089 79611387
Lung disorder 29.61 11.83 55 131857 80502 79531974
Male sexual dysfunction 29.55 11.83 12 131900 223 79612253
Hypervolaemia 29.42 11.83 17 131895 42673 79569803
Blood creatinine increased 29.41 11.83 144 131768 154913 79457563
Homeless 29.39 11.83 10 131902 110 79612366
Device related infection 29.38 11.83 10 131902 34284 79578192
COVID-19 pneumonia 29.29 11.83 6 131906 28843 79583633
Subdural haematoma 29.03 11.83 8 131904 31426 79581050
Intentional product misuse 28.93 11.83 262 131650 94903 79517573
Tumour lysis syndrome 28.86 11.83 3 131909 23936 79588540
Distractibility 28.85 11.83 17 131895 728 79611748
Respiratory failure 28.84 11.83 178 131734 180733 79431743
Intellectual disability 28.72 11.83 21 131891 1299 79611177
Food craving 28.67 11.83 23 131889 1634 79610842
Rash erythematous 28.57 11.83 32 131880 57737 79554739
Full blood count decreased 28.46 11.83 5 131907 26814 79585662
Sudden cardiac death 28.41 11.83 39 131873 5186 79607290
Drug dependence 28.27 11.83 138 131774 40631 79571845
Loss of consciousness 28.24 11.83 412 131500 167531 79444945
Fungal infection 28.24 11.83 17 131895 41731 79570745
Emotional distress 28.22 11.83 136 131776 39833 79572643
Drug withdrawal syndrome 28.13 11.83 123 131789 34595 79577881
Heat stroke 28.11 11.83 23 131889 1680 79610796
Major depression 28.01 11.83 52 131860 8928 79603548
Poor quality sleep 27.95 11.83 92 131820 22630 79589846
Lung neoplasm malignant 27.76 11.83 6 131906 27786 79584690
High-grade B-cell lymphoma 27.75 11.83 10 131902 132 79612344
Lactic acidosis 27.71 11.83 46 131866 70313 79542163
Haemorrhage intracranial 27.54 11.83 5 131907 26188 79586288
Blood pressure diastolic decreased 27.33 11.83 8 131904 30208 79582268
Verbal abuse 27.27 11.83 12 131900 274 79612202
Target skin lesion 27.21 11.83 10 131902 140 79612336
Rebound psychosis 27.21 11.83 13 131899 361 79612115
Delusional perception 27.01 11.83 13 131899 367 79612109
Leukopenia 26.86 11.83 303 131609 116210 79496266
Coordination abnormal 26.82 11.83 76 131836 17236 79595240
Adrenal insufficiency 26.78 11.83 7 131905 28480 79583996
Rash maculo-papular 26.72 11.83 32 131880 56046 79556430
Premature labour 26.70 11.83 49 131863 8341 79604135
Pneumothorax 26.55 11.83 7 131905 28316 79584160
Bundle branch block right 26.54 11.83 58 131854 11193 79601283
Dissociation 26.51 11.83 33 131879 3988 79608488
Bronchiectasis 26.50 11.83 3 131909 22383 79590093
Hip fracture 26.30 11.83 9 131903 30752 79581724
Renal tubular necrosis 25.85 11.83 5 131907 25034 79587442
Bacteraemia 25.74 11.83 11 131901 32813 79579663
Bladder dilatation 25.68 11.83 24 131888 2095 79610381
Haemophagocytic lymphohistiocytosis 25.66 11.83 3 131909 21834 79590642
Night sweats 25.60 11.83 29 131883 52066 79560410
Immunodeficiency 25.56 11.83 3 131909 21765 79590711
Obstructive airways disorder 25.55 11.83 10 131902 31449 79581027
Child abuse 25.51 11.83 13 131899 416 79612060
Ejaculation disorder 25.45 11.83 14 131898 525 79611951
Hypocalcaemia 25.41 11.83 27 131885 49897 79562579
Polyuria 25.33 11.83 68 131844 14946 79597530
Diabetic hyperosmolar coma 25.26 11.83 16 131896 781 79611695
Soft tissue injury 25.18 11.83 22 131890 1759 79610717
Osteonecrosis 25.07 11.83 10 131902 31085 79581391
Oligospermia 25.04 11.83 7 131905 37 79612439
Uterine dilation and curettage 24.83 11.83 14 131898 551 79611925
Apraxia 24.71 11.83 27 131885 2840 79609636
Rhinorrhoea 24.52 11.83 56 131856 76018 79536458
Hypersomnia 24.50 11.83 89 131823 22997 79589479
Personal relationship issue 24.42 11.83 10 131902 190 79612286
Spasmodic dysphonia 24.38 11.83 11 131901 267 79612209
Hypometabolism 24.30 11.83 9 131903 129 79612347
Thermal burn 24.29 11.83 43 131869 7117 79605359
High density lipoprotein decreased 24.20 11.83 34 131878 4621 79607855
Asthma 24.18 11.83 128 131784 134967 79477509
Antisocial behaviour 24.17 11.83 15 131897 706 79611770
Activation syndrome 24.12 11.83 11 131901 274 79612202
Basilar artery occlusion 24.09 11.83 10 131902 197 79612279
Post-traumatic neck syndrome 24.01 11.83 23 131889 2071 79610405
Intention tremor 23.70 11.83 15 131897 731 79611745
Oral herpes 23.53 11.83 8 131904 27446 79585030
Medication error 23.49 11.83 194 131718 68448 79544028
Disorientation 23.43 11.83 181 131731 62595 79549881
Gout 23.42 11.83 6 131906 24743 79587733
Compulsions 23.21 11.83 12 131900 396 79612080
Hypomagnesaemia 23.18 11.83 26 131886 46885 79565591
Cystitis 23.15 11.83 32 131880 52700 79559776
Thrombotic microangiopathy 23.14 11.83 3 131909 20166 79592310
Osteomyelitis 22.77 11.83 13 131899 32852 79579624
Electroconvulsive therapy 22.67 11.83 8 131904 99 79612377
Cellulitis 22.63 11.83 98 131814 108962 79503514
Poor personal hygiene 22.62 11.83 13 131899 531 79611945
Foot deformity 22.47 11.83 6 131906 24068 79588408
Pregnancy with implant contraceptive 22.45 11.83 21 131891 1835 79610641
Screaming 22.36 11.83 30 131882 3903 79608573
Hereditary ataxia 22.25 11.83 6 131906 27 79612449
Grimacing 22.22 11.83 14 131898 677 79611799
Bladder cancer 22.17 11.83 3 131909 19523 79592953
Theft 22.16 11.83 10 131902 243 79612233
Cerebrovascular accident 22.13 11.83 158 131754 155134 79457342
Cholestasis of pregnancy 22.06 11.83 16 131896 977 79611499
Clostridium difficile colitis 22.04 11.83 13 131899 32270 79580206
Tongue spasm 22.04 11.83 8 131904 108 79612368
Liver disorder 21.99 11.83 55 131857 72362 79540114
Breast feeding 21.83 11.83 14 131898 698 79611778
Benign ethnic neutropenia 21.83 11.83 7 131905 63 79612413
Muscular weakness 21.72 11.83 166 131746 160563 79451913
Blood pressure diastolic abnormal 21.69 11.83 3 131909 19199 79593277
Excessive sexual fantasies 21.62 11.83 4 131908 0 79612476
Memory impairment 21.58 11.83 281 131631 111453 79501023
Compulsive hoarding 21.54 11.83 7 131905 66 79612410
Persistent depressive disorder 21.43 11.83 17 131895 1188 79611288
Injection site reaction 21.40 11.83 36 131876 54749 79557727
Disease recurrence 21.05 11.83 135 131777 43974 79568502
Fear 21.04 11.83 82 131830 21904 79590572
Hypotension 21.01 11.83 561 131351 439756 79172720
Nodule 20.96 11.83 6 131906 22988 79589488
Haemorrhoids 20.94 11.83 11 131901 29117 79583359
Selective mutism 20.83 11.83 7 131905 74 79612402
Intermenstrual bleeding 20.82 11.83 36 131876 5848 79606628
Myocarditis septic 20.82 11.83 6 131906 36 79612440
Chronic obstructive pulmonary disease 20.77 11.83 72 131840 85347 79527129
Slow speech 20.77 11.83 23 131889 2455 79610021
Neuralgia 20.68 11.83 15 131897 33369 79579107
Atelectasis 20.63 11.83 14 131898 32243 79580233
Blood pressure increased 20.53 11.83 237 131675 211123 79401353
Renal hypertension 20.52 11.83 9 131903 204 79612272
Hypoalbuminaemia 20.47 11.83 5 131907 21292 79591184
Eating disorder 20.47 11.83 78 131834 20619 79591857
Dysphemia 20.46 11.83 27 131885 3457 79609019
Type 2 diabetes mellitus 20.38 11.83 163 131749 56959 79555517
Nasal congestion 20.37 11.83 62 131850 76490 79535986
Posterior reversible encephalopathy syndrome 20.30 11.83 9 131903 26272 79586204
Body mass index decreased 20.24 11.83 13 131899 650 79611826
Dermatillomania 20.24 11.83 9 131903 211 79612265
Emotional disorder 20.22 11.83 61 131851 14326 79598150
Concussion 20.20 11.83 47 131865 9456 79603020
Initial insomnia 20.19 11.83 39 131873 6899 79605577
Poriomania 20.16 11.83 9 131903 213 79612263
Nephrectasia 20.12 11.83 5 131907 15 79612461
Lymphocyte count abnormal 20.12 11.83 18 131894 1485 79610991
Injection site pain 20.04 11.83 129 131783 129709 79482767
Pulmonary arterial hypertension 19.97 11.83 11 131901 28355 79584121
Injection site bruising 19.96 11.83 23 131889 40979 79571497
Abortion threatened 19.96 11.83 11 131901 414 79612062
CADASIL 19.91 11.83 6 131906 43 79612433
Musculoskeletal chest pain 19.90 11.83 8 131904 24756 79587720
Rhinalgia 19.89 11.83 22 131890 2345 79610131
Hypokalaemia 19.82 11.83 148 131764 143892 79468584
Hemiparesis 19.82 11.83 16 131896 33717 79578759
Skin lesion 19.81 11.83 24 131888 41820 79570656
Body dysmorphic disorder 19.77 11.83 10 131902 315 79612161
Anterograde amnesia 19.75 11.83 13 131899 678 79611798
No adverse event 19.74 11.83 117 131795 37075 79575401
Iatrogenic injury 19.71 11.83 18 131894 1525 79610951
Morning sickness 19.68 11.83 12 131900 547 79611929
Dementia with Lewy bodies 19.64 11.83 14 131898 832 79611644
Joint hyperextension 19.60 11.83 10 131902 321 79612155
Drug monitoring procedure not performed 19.58 11.83 15 131897 996 79611480
Femur fracture 19.56 11.83 21 131891 38631 79573845
Faeces discoloured 19.51 11.83 12 131900 29115 79583361
Social anxiety disorder 19.45 11.83 12 131900 559 79611917
Protrusion tongue 19.44 11.83 11 131901 436 79612040
Shoplifting 19.39 11.83 4 131908 3 79612473
Bone disorder 19.35 11.83 4 131908 19109 79593367
Non-high-density lipoprotein cholesterol increased 19.32 11.83 10 131902 331 79612145
Paraesthesia oral 19.30 11.83 5 131907 20466 79592010
Facial nerve disorder 19.23 11.83 13 131899 709 79611767
Nephropathy toxic 19.23 11.83 5 131907 20414 79592062
Fear of weight gain 19.22 11.83 5 131907 19 79612457
Sluggishness 19.19 11.83 37 131875 6535 79605941
Candida infection 19.08 11.83 21 131891 38193 79574283
Hypoaesthesia 19.06 11.83 197 131715 179155 79433321
Excessive masturbation 19.05 11.83 7 131905 98 79612378
Nephrolithiasis 19.04 11.83 37 131875 53254 79559222
Chemical burn 19.03 11.83 12 131900 581 79611895
Sexual abuse 19.00 11.83 9 131903 245 79612231
Locked-in syndrome 18.96 11.83 13 131899 726 79611750
Hunger 18.94 11.83 33 131879 5395 79607081
Twin pregnancy 18.92 11.83 14 131898 882 79611594
Pseudomyopia 18.73 11.83 7 131905 103 79612373
Meningitis streptococcal 18.71 11.83 8 131904 170 79612306
Sternal fracture 18.70 11.83 22 131890 2508 79609968
Tendonitis 18.66 11.83 8 131904 23822 79588654
Transfusion 18.66 11.83 6 131906 21324 79591152
Neuroleptic-induced deficit syndrome 18.64 11.83 5 131907 22 79612454
Communication disorder 18.54 11.83 28 131884 4062 79608414
Gastrooesophageal reflux disease 18.52 11.83 99 131813 104147 79508329
Helplessness 18.50 11.83 10 131902 362 79612114
Decreased activity 18.48 11.83 43 131869 8651 79603825
Gastroenteritis viral 18.42 11.83 9 131903 24822 79587654
Angina pectoris 18.41 11.83 36 131876 51696 79560780
Taciturnity 18.39 11.83 4 131908 5 79612471
Disorganised speech 18.35 11.83 20 131892 2097 79610379
Full blood count abnormal 18.34 11.83 24 131888 40450 79572026
Nightmare 18.26 11.83 88 131824 25773 79586703
Polyhydramnios 18.05 11.83 18 131894 1702 79610774
Hot flush 18.01 11.83 40 131872 54837 79557639
Obsessive-compulsive symptom 17.97 11.83 8 131904 188 79612288
Respiratory disorder 17.96 11.83 29 131883 44827 79567649
Adjusted calcium increased 17.89 11.83 6 131906 63 79612413
Angioedema 17.88 11.83 65 131847 75970 79536506
Oropharyngeal pain 17.73 11.83 107 131805 109246 79503230
Grip strength decreased 17.68 11.83 7 131905 21862 79590614
Nervousness 17.66 11.83 105 131807 33310 79579166
Hypotonia 17.56 11.83 54 131858 12816 79599660
Abdominal pain lower 17.54 11.83 16 131896 31766 79580710
Polyneuropathy 17.54 11.83 9 131903 24142 79588334
Metastases to central nervous system 17.49 11.83 3 131909 16372 79596104
Product reconstitution quality issue 17.48 11.83 8 131904 201 79612275
Megacolon 17.39 11.83 25 131887 3470 79609006
Swelling face 17.33 11.83 60 131852 71152 79541324
Localised infection 17.31 11.83 22 131890 37553 79574923
Metabolic acidosis 17.22 11.83 74 131838 82455 79530021
Multiple drug therapy 17.19 11.83 27 131885 4051 79608425
Diabetes insipidus 17.19 11.83 31 131881 5206 79607270
Confusional arousal 17.02 11.83 6 131906 74 79612402
Therapeutic product effect incomplete 17.01 11.83 329 131583 141316 79471160
Bronchospasm 16.99 11.83 10 131902 24849 79587627
Troponin increased 16.98 11.83 70 131842 19185 79593291
Blood ketone body 16.90 11.83 7 131905 137 79612339
Violence-related symptom 16.75 11.83 12 131900 719 79611757
Tourette's disorder 16.59 11.83 6 131906 80 79612396
Drug ineffective for unapproved indication 16.57 11.83 143 131769 51095 79561381
Pyramidal tract syndrome 16.50 11.83 11 131901 586 79611890
Anuria 16.48 11.83 7 131905 20956 79591520
Blood thyroid stimulating hormone decreased 16.47 11.83 32 131880 5684 79606792
Delusional disorder, erotomanic type 16.45 11.83 5 131907 37 79612439
Delusion of reference 16.45 11.83 7 131905 147 79612329
Narcolepsy 16.43 11.83 15 131897 1271 79611205
Liver injury 16.42 11.83 44 131868 56570 79555906
Malignant catatonia 16.42 11.83 10 131902 455 79612021
Pseudomonas infection 16.40 11.83 7 131905 20896 79591580
Oesophagitis 16.27 11.83 10 131902 24279 79588197
Oral candidiasis 16.26 11.83 15 131897 29613 79582863
Substance use 16.23 11.83 13 131899 921 79611555
Complicated fracture 16.22 11.83 3 131909 0 79612476
Mean cell haemoglobin concentration decreased 16.18 11.83 28 131884 4551 79607925
Procedural pain 16.18 11.83 9 131903 23075 79589401
Hypoglycaemia 16.16 11.83 100 131812 101494 79510982
Hepatic failure 15.99 11.83 50 131862 61162 79551314
Skin necrosis 15.98 11.83 5 131907 18082 79594394
Petechiae 15.95 11.83 7 131905 20558 79591918
Myopathy 15.95 11.83 7 131905 20556 79591920
Spinal fracture 15.93 11.83 5 131907 18049 79594427
Adverse drug reaction 15.91 11.83 174 131738 66218 79546258
Incorrect dose administered 15.77 11.83 195 131717 76435 79536041
Gastritis 15.73 11.83 35 131877 47958 79564518
Post procedural complication 15.71 11.83 10 131902 23819 79588657
Hypoacusis 15.69 11.83 16 131896 30134 79582342
Erection increased 15.58 11.83 9 131903 371 79612105
Device malfunction 15.57 11.83 8 131904 21440 79591036
Musculoskeletal disorder 15.57 11.83 8 131904 21440 79591036
Respiratory tract infection 15.56 11.83 36 131876 48653 79563823
Therapy cessation 15.55 11.83 111 131801 37451 79575025
Condition aggravated 15.54 11.83 994 130918 500130 79112346
Skin cancer 15.54 11.83 3 131909 15037 79597439
Attention deficit hyperactivity disorder 15.49 11.83 23 131889 3286 79609190
Ulcer 15.49 11.83 16 131896 29956 79582520
Urine amphetamine positive 15.48 11.83 6 131906 98 79612378
Upper gastrointestinal haemorrhage 15.43 11.83 28 131884 41352 79571124
Prader-Willi syndrome 15.42 11.83 4 131908 15 79612461
Haemorrhage 15.39 11.83 88 131824 91030 79521446
Juvenile idiopathic arthritis 15.39 11.83 28 131884 4735 79607741
Emphysema 15.33 11.83 4 131908 16296 79596180
Shock haemorrhagic 15.29 11.83 7 131905 20053 79592423
Dyspepsia 15.28 11.83 111 131801 108576 79503900
Libido disorder 15.26 11.83 8 131904 272 79612204
Cholangitis infective 15.25 11.83 11 131901 666 79611810
Burning sensation 15.24 11.83 48 131864 58584 79553892
Rales 15.22 11.83 7 131905 19994 79592482
Neuropsychiatric symptoms 15.21 11.83 15 131897 1400 79611076
Ejaculation delayed 15.18 11.83 7 131905 179 79612297
Waxy flexibility 15.18 11.83 8 131904 275 79612201
Dysbiosis 15.15 11.83 14 131898 1205 79611271
Toxic epidermal necrolysis 15.04 11.83 32 131880 44549 79567927
Gender dysphoria 15.04 11.83 5 131907 51 79612425
Echopraxia 15.04 11.83 5 131907 51 79612425
Head banging 15.03 11.83 10 131902 531 79611945
Pulmonary oedema 15.03 11.83 85 131827 88169 79524307
Decreased interest 14.93 11.83 24 131888 3673 79608803
Post-traumatic stress disorder 14.90 11.83 28 131884 4853 79607623
Diet refusal 14.88 11.83 12 131900 859 79611617
Therapeutic product effective for unapproved indication 14.85 11.83 6 131906 110 79612366
Hyponatriuria 14.84 11.83 4 131908 18 79612458
Muscle tightness 14.75 11.83 51 131861 12863 79599613
Imprisonment 14.67 11.83 10 131902 553 79611923
Breath odour 14.66 11.83 16 131896 1680 79610796
Affective ambivalence 14.66 11.83 4 131908 19 79612457
Disruptive mood dysregulation disorder 14.66 11.83 4 131908 19 79612457
Excessive eye blinking 14.62 11.83 16 131896 1685 79610791
Influenza like illness 14.53 11.83 65 131847 71642 79540834
Hepatic cirrhosis 14.52 11.83 22 131890 34884 79577592
Sleep disorder due to a general medical condition 14.43 11.83 3 131909 14274 79598202
Neutrophilia 14.42 11.83 37 131875 7914 79604562
Impaired self-care 14.41 11.83 20 131892 2687 79609789
Renal injury 14.39 11.83 5 131907 16922 79595554
Squamous cell carcinoma 14.38 11.83 4 131908 15618 79596858
Dyskinesia oesophageal 14.38 11.83 5 131907 59 79612417
Exostosis 14.30 11.83 5 131907 16853 79595623
Mouth ulceration 14.30 11.83 26 131886 38368 79574108
Lethargy 14.28 11.83 201 131711 81091 79531385
Injection site haemorrhage 14.26 11.83 15 131897 27855 79584621
Hyporeflexia 14.19 11.83 23 131889 3545 79608931
Haematemesis 14.14 11.83 42 131870 52222 79560254
Spleen congestion 14.10 11.83 9 131903 445 79612031
Fall 14.10 11.83 661 131251 486968 79125508
Unevaluable event 14.10 11.83 46 131866 55539 79556937
Immune thrombocytopenia 13.91 11.83 6 131906 17799 79594677
Congestive cardiomyopathy 13.87 11.83 47 131865 11733 79600743
Anhedonia 13.80 11.83 55 131857 14843 79597633
Gross motor delay 13.80 11.83 6 131906 133 79612343
Feeling of despair 13.77 11.83 20 131892 2801 79609675
Neck pain 13.75 11.83 71 131841 75346 79537130
Pituitary tumour benign 13.67 11.83 19 131893 2557 79609919
Confusional state 13.64 11.83 650 131262 317347 79295129
Hypophosphataemia 13.62 11.83 8 131904 19905 79592571
Biliary tract infection 13.61 11.83 14 131898 1374 79611102
Loss of employment 13.60 11.83 19 131893 2568 79609908
Gastric haemorrhage 13.58 11.83 4 131908 15046 79597430
Pulmonary hypertension 13.47 11.83 38 131874 48042 79564434
Injection site swelling 13.39 11.83 37 131875 47095 79565381
Haematoma 13.37 11.83 43 131869 52152 79560324
Pseudodementia 13.35 11.83 4 131908 28 79612448
Lower gastrointestinal haemorrhage 13.30 11.83 5 131907 16120 79596356
Self esteem inflated 13.28 11.83 3 131909 5 79612471
Neoplasm malignant 13.28 11.83 20 131892 31790 79580686
Menstrual disorder 13.25 11.83 24 131888 4043 79608433
Plagiocephaly 13.23 11.83 4 131908 29 79612447
Product use issue 13.21 11.83 447 131465 209375 79403101
Sputum discoloured 13.17 11.83 10 131902 21733 79590743
Nervous system disorder 13.14 11.83 15 131897 26841 79585635
Sexually transmitted disease 13.14 11.83 6 131906 150 79612326
Chorea 13.08 11.83 18 131894 2399 79610077
Lipase increased 13.08 11.83 58 131854 16408 79596068
Skin exfoliation 13.02 11.83 47 131865 55053 79557423
Hyperosmolar state 12.94 11.83 10 131902 673 79611803
Intrapartum haemorrhage 12.93 11.83 3 131909 6 79612470
Flight of ideas 12.90 11.83 11 131901 851 79611625
Paralogism 12.89 11.83 4 131908 32 79612444
Scrotal haematoma 12.88 11.83 5 131907 82 79612394
Limb injury 12.88 11.83 18 131894 29510 79582966
Merycism 12.86 11.83 7 131905 257 79612219
Drug eruption 12.85 11.83 34 131878 43901 79568575
Energy increased 12.84 11.83 21 131891 3261 79609215
Psoriasis 12.83 11.83 91 131821 89496 79522980
Asocial behaviour 12.83 11.83 5 131907 83 79612393
Induced labour 12.79 11.83 11 131901 861 79611615
Urosepsis 12.75 11.83 15 131897 26480 79585996
Epstein-Barr virus infection 12.71 11.83 4 131908 14412 79598064
Joint effusion 12.66 11.83 7 131905 18007 79594469
Breast discharge 12.61 11.83 10 131902 699 79611777
Premature delivery 12.57 11.83 74 131838 23393 79589083
Exposure during pregnancy 12.52 11.83 236 131676 100896 79511580
Clostridium difficile infection 12.51 11.83 33 131879 42652 79569824
Saccadic eye movement 12.51 11.83 6 131906 168 79612308
Neurological examination normal 12.47 11.83 4 131908 36 79612440
Ear pain 12.47 11.83 22 131890 32847 79579629
Breast cancer 12.47 11.83 23 131889 33758 79578718
Tooth disorder 12.46 11.83 15 131897 26218 79586258
Acute coronary syndrome 12.45 11.83 10 131902 21123 79591353
Right ventricular systolic pressure decreased 12.41 11.83 5 131907 91 79612385
Food refusal 12.39 11.83 9 131903 551 79611925
Pulseless electrical activity 12.36 11.83 4 131908 14156 79598320
Spinal pain 12.32 11.83 5 131907 15387 79597089
Asphyxia 12.28 11.83 45 131867 11675 79600801
Urate nephropathy 12.25 11.83 6 131906 176 79612300
Psychotic disorder due to a general medical condition 12.22 11.83 7 131905 284 79612192
Irregular sleep phase 12.16 11.83 5 131907 96 79612380
Cataplexy 12.14 11.83 11 131901 923 79611553
Patient dissatisfaction with treatment 12.13 11.83 6 131906 180 79612296
Myalgia 12.13 11.83 225 131687 185416 79427060
Hyponatraemia 12.11 11.83 214 131698 177634 79434842
Panic reaction 12.11 11.83 25 131887 4640 79607836
Electrocardiogram PR prolongation 12.09 11.83 14 131898 1569 79610907
Weight 12.01 11.83 4 131908 41 79612435
Female sexual dysfunction 12.01 11.83 4 131908 41 79612435
Trichotillomania 12.01 11.83 6 131906 184 79612292
Flushing 12.00 11.83 91 131821 88177 79524299
Tri-iodothyronine decreased 11.98 11.83 7 131905 295 79612181
Hyperammonaemia 11.97 11.83 43 131869 11050 79601426
Wolff-Parkinson-White syndrome 11.96 11.83 7 131905 296 79612180
Blood urea increased 11.95 11.83 41 131871 48749 79563727
Premature baby 11.93 11.83 22 131890 3758 79608718
Menstruation irregular 11.92 11.83 26 131886 5010 79607466
Insulin resistance 11.91 11.83 13 131899 1366 79611110
Coronary artery stenosis 11.87 11.83 3 131909 12481 79599995
Sinus arrhythmia 11.85 11.83 16 131896 2094 79610382
Abnormal weight gain 11.84 11.83 18 131894 2626 79609850

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enterococcal sepsis 28.03 25.07 10 1019 10 88753
Right ventricular false tendon 28.03 25.07 10 1019 10 88753

Pharmacologic Action:

SourceCodeDescription
ATC N05AX12 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Other antipsychotics
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D000928 Antidepressive Agents
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018492 Dopamine Antagonists
MeSH PA D065127 Dopamine D2 Receptor Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D058830 Serotonin 5-HT2 Receptor Antagonists
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35941 serotonin agonists
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:65191 atypical antipsychotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Infantile autism indication 408857007
Agitation associated with Bipolar Mania indication
Depression Treatment Adjunct indication
Agitation associated with Schizophrenia indication
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Alzheimer's disease contraindication 26929004 DOID:10652
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Hyperlipidemia contraindication 55822004 DOID:1168
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Leukopenia contraindication 84828003 DOID:615
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Metabolic syndrome X contraindication 237602007 DOID:14221
Esophageal dysmotility contraindication 266434009 DOID:9192
Neutropenic disorder contraindication 303011007 DOID:1227
At risk for aspiration contraindication 371736008
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.84 Basic
pKa2 0.67 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
9.75MG/1.3ML (7.5MG/ML) ABILIFY OTSUKA N021866 Sept. 20, 2006 DISCN INJECTABLE INTRAMUSCULAR 7115587 July 21, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10517951 April 23, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10517951 April 23, 2033 TREATMENT OF SCHIZOPHRENIA
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11097007 April 23, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11097007 April 23, 2033 TREATMENT OF SCHIZOPHRENIA
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11638757 April 23, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
720MG/2.4ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11638757 April 23, 2033 TREATMENT OF SCHIZOPHRENIA
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10517951 April 23, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10517951 April 23, 2033 TREATMENT OF SCHIZOPHRENIA
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11097007 April 23, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11097007 April 23, 2033 TREATMENT OF SCHIZOPHRENIA
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11638757 April 23, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
960MG/3.2ML (300MG/ML) ABILIFY ASIMTUFII OTSUKA N217006 April 27, 2023 RX SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11638757 April 23, 2033 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11344547 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11400087 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR PARTIAL AGONIST Ki 8.71 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1A GPCR PARTIAL AGONIST Ki 8.15 WOMBAT-PK DRUG LABEL
Alpha-2A adrenergic receptor GPCR Ki 7.13 PDSP
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 6.22 CHEMBL
Multidrug resistance protein 1 Transporter IC50 6.11 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.83 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.68 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 9.44 PDSP
5-hydroxytryptamine receptor 2C GPCR Ki 7.36 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 6.51 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.69 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 7.24 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.99 PDSP
D(3) dopamine receptor GPCR Ki 8.53 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 5.68 PDSP
Histamine H1 receptor GPCR Ki 7.22 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 5.17 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.46 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5.33 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.82 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.63 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.10 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 7.20 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.42 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.49 PDSP
D(4) dopamine receptor GPCR Ki 6.65 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.20 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.46 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 5.91 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.10 PDSP
Histamine H3 receptor GPCR Ki 5.63 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 6.85 PDSP
Histone H1.0 Nuclear other Ki 7.55 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.79 PDSP
D(1A) dopamine receptor GPCR Ki 6.06 PDSP
Histamine H1 receptor GPCR Ki 7 CHEMBL
D(2) dopamine receptor GPCR Ki 9.10 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 9.40 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.97 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.15 CHEMBL
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 7.80 IUPHAR
D(1A) dopamine receptor GPCR Ki 9.10 CHEMBL
D(3) dopamine receptor GPCR IC50 7.42 CHEMBL
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 IUPHAR
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 2C GPCR IC50 7.59 CHEMBL

External reference:

IDSource
4021367 VUID
N0000148786 NUI
D01164 KEGG_DRUG
352393 RXNORM
C0299792 UMLSCUI
CHEBI:31236 CHEBI
9SC PDB_CHEM_ID
CHEMBL1112 ChEMBL_ID
D000068180 MESH_DESCRIPTOR_UI
DB01238 DRUGBANK_ID
34 IUPHAR_LIGAND_ID
7477 INN_ID
82VFR53I78 UNII
60795 PUBCHEM_CID
17034 MMSL
231328 MMSL
45384 MMSL
d04825 MMSL
406784005 SNOMEDCT_US
406785006 SNOMEDCT_US
4021367 VANDF
009852 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-8259 TABLET 5 mg ORAL ANDA 33 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-8375 TABLET 5 mg ORAL ANDA 32 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-8375 TABLET 5 mg ORAL ANDA 32 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6509 TABLET 2 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6509 TABLET 2 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6510 TABLET 5 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6510 TABLET 5 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6511 TABLET 10 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6511 TABLET 10 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6512 TABLET 15 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6512 TABLET 15 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6513 TABLET 20 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6513 TABLET 20 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6514 TABLET 30 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6514 TABLET 30 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6655 TABLET 2 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6656 TABLET 5 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6656 TABLET 5 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-216 TABLET 2 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-216 TABLET 2 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-216 TABLET 2 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-216 TABLET 2 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-217 TABLET 5 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-217 TABLET 5 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-217 TABLET 5 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-217 TABLET 5 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-218 TABLET 10 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-218 TABLET 10 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-218 TABLET 10 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-218 TABLET 10 mg ORAL ANDA 31 sections